

Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts

C.Ferretti^{1,2}, L.Bruni^{1,2}, V.Dangles-Marie¹, A.P.Pecking³ and D.Bellet^{1,3,4}

¹UMR 8149 CNRS, IFR 71, Université René Descartes, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, Paris, France,

²Department of Pediatrics, Obstetrics and Reproductive Medicine, University of Siena, Siena, Italy and ³Service de Médecine Nucléaire, Centre René Huguenin, Saint-Cloud, France

⁴To whom correspondence should be addressed at: Laboratoire de Physiopathologie Hépatique et Laboratoire d'Immunologie, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, 4 Avenue de l'Observatoire, 75 006 Paris, France. E-mail: dominique.bellet@univ-paris5.fr

Trophoblast research over the past decades has underlined the striking similarities between the proliferative, migratory and invasive properties of placental cells and those of cancer cells. This review recapitulates the numerous key molecules, proto-oncogenes, growth factors, receptors, enzymes, hormones, peptides and tumour-associated antigens (TAAs) expressed by both trophoblastic and cancer cells in an attempt to evaluate the genes and proteins forming molecular circuits and regulating the similar behaviours of these cells. Among the autocrine and paracrine loops that might be involved in the strong proliferative capacity of trophoblastic and cancer cells, epidermal growth factor (EGF)/EGF receptor (EGFR), hepatocyte growth factor (HGF)/HGF receptor (HGFR) (Met) and vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) loops may play a predominant role. Similar mechanisms of migration and invasion displayed by trophoblastic and malignant cells comprise alterations in the adhesion molecule phenotype, including the increased expression of $\alpha 1\beta 1$ and $\alpha v\beta 3$ integrin receptors, whereas another critical molecular event is the down-regulation of the cell adhesion molecule E-cadherin. Among proteases that may play an active role in the invasive capacities of these cells, accumulating evidence suggests that matrix metalloproteinase-9 (MMP-9) expression/activation is a prerequisite. Finally, an overview of molecular circuitries shared by trophoblast and cancer cells reveals that the activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT axis has recently emerged as a central feature of signalling pathways used by these cells to achieve their proliferative, migratory and invasive processes.

Key words: cell signalling/pregnancy/trophoblasts

Introduction

The human placenta undergoes dramatic structural reorganization during pregnancy so as to be functionally synchronized with the development of embryonic fetal and maternal compartments (Ohlsson *et al.*, 1993). Although the placenta is a normal tissue, its constituent cells, the trophoblastic cells, share several common features with malignant cells. Their high cell proliferation, their lack of cell-contact inhibition, their migratory and invasive properties as well as their capacity to escape effectors of the immune system, in particular during the first trimester of pregnancy, have led to the definition of the trophoblast as a 'pseudo-malignant' type of tissue or as a 'physiological metastasis' (Strickland and Richards, 1992; Genbacev *et al.*, 1997; Redman, 1997; Even-Ram *et al.*, 1998; Mullen, 1998). This review will focus on subpopulations of normal trophoblastic cells that closely mimic malignant cells. After the presentation of behavioural resemblances between

normal trophoblastic and malignant non-trophoblastic cells, the many key molecules commonly expressed by these cells will be described in an attempt to gauge the genes and proteins that participate in molecular circuits implicated in their similar behaviours. Moreover, this review will show how the complex body of knowledge generated by trophoblast and cancer research during the last few decades is in line with the hypothesis that trophoblastic and cancer cells use comparable mechanisms implemented by identical molecular circuitries to achieve their proliferative, migratory and invasive processes. Finally, the comparison of placenta and tumours will be crucial to our knowledge of major signalling cascades and key molecules implicated in invasion and migration processes. The identification of these pathways and molecules could provide novel targets for the diagnosis and treatment of both cancer diseases and pathological pregnancies, enabling the translation of basic research discoveries into clinical applications.

Comparable behaviours of normal trophoblastic and malignant non-trophoblastic cells: proliferation and migration/invasion

In humans, after fertilization in the oviduct, a series of symmetrical cell divisions create a mass of totipotent cells, the morula, still enclosed within the zona pellucida. The first differentiation event occurs after the compaction of the morula with the formation of the blastocyst. Cells that lie outside of the morula become trophectoderm, the first epithelium in mammals, and trophoblasts are derived from trophectoderm cells present in the blastocyst. They form the fetal compartment (placenta) of the fetal–maternal interface during pregnancy and are extra-embryonic tissues. When the blastocyst invades the decidua of the uterine wall during implantation (6th–7th day after ovulation), trophoblast cells are on the front line and become invasive as they differentiate (Boyd, 1980; Redman *et al.*, 1993; Cross *et al.*, 1994; Loke and King, 1995). Trophoblasts include various populations of cells with differing morphologies. At an early stage, the founding population comprises cytotrophoblast stem cells attached to the trophoblast basement membrane and actively proliferating. These trophoblast cells follow two differentiation pathways, the villous and extravillous pathways, and differentiate into villous and extravillous populations. In the villous pathway, villous cytotrophoblasts (vCTBs) remain in the fetal compartment, where they fuse to form multinucleate, weakly proliferating syncytiotrophoblasts (STs) that cover the floating chorionic villi (Figure 1). These villi, which are in direct contact with maternal blood in the intervillous space, perform nutrient and gas exchange for the fetus. In the other pathway, which is the focus of the present review, a subset of proliferative cytotrophoblast cells differentiates into extravillous (intermediate) cytotrophoblasts (evCTBs). These cells leave the trophoblast basement membrane and form columns of non-polarized cells, the anchoring chorionic villi that attach to and then penetrate the uterine wall. At the base of anchoring villi, evCTBs form clusters of proliferating cells (proliferating evCTBs) (Lacroix *et al.*, 2005). As they further differentiate, evCTB cells lose the ability to divide

within cell columns and become mobile and highly invasive (invading evCTBs). Moreover, the cytotrophoblast cell columns spread laterally and fuse with the neighbouring columns to form a cytotrophoblast shell that encircles the embryonic sac. The invading evCTB cells arise from this cytotrophoblast shell. Amongst the invading (intermediate) evCTB cells, interstitial evCTB cells invade the decidualized endometrium and the proximal third of the myometrium (interstitial invasion), whereas some evCTB (endovascular evCTB) cells invade the uterine spiral arteries (endovascular invasion). During interstitial invasion, interstitial evCTB cells, either individually or in small clusters, blend with resident decidual, myometrial and immune cells. Following invasion into the decidua, the interstitial trophoblastic cells become isolated fusiform pleiomorphic cells. By 8 weeks of pregnancy, interstitial evCTB cells have extensively colonized the full thickness of the uterine mucosa to reach the decidual–myometrial border. As the cells move deeper into the decidua, interstitial evCTB cells become multinucleated and more rounded (placental bed giant cells). During the second trimester, there is further invasion into the inner myometrium, and most of the trophoblast cells here possess the morphology of placental bed giant cells.

Thus, the behaviour of highly proliferative vCTB stem cells and proliferative evCTBs (intermediate proliferating evCTBs at the base of cell columns) closely resembles that of transformed cells displaying a tumorigenic phenotype after neoplastic transformation. This transformation is accomplished by localized tumours in the absence of metastasis (Gupta *et al.*, 2005). Both cytotrophoblastic cells and cancer cells are highly proliferative and display a lack of cell-contact inhibition, two major traits shared by all types of human tumours. However, in contrast to that of tumour cells, the proliferation of evCTB cells is tightly regulated, and these cells quit cell growth during invasive differentiation (Pollheimer and Knofler, 2005). Following the differentiation of proliferative evCTBs into migratory and invasive evCTBs (intermediate invading evCTBs of cell columns, interstitial evCTBs and endovascular evCTBs), the behaviour of invasive evCTBs closely resembles




Figure 1. Left: immunohistochemical staining of early placenta with antibody to cytokeratin 07. This antibody stains (brown colour) the villous cytotrophoblasts (vCTBs) and the extravillous cytotrophoblasts (evCTBs) but does not stain the syncytiotrophoblasts (STs) (blue colour). Middle: Schematic representation of floating and anchoring villi. Right: Diagram of different trophoblast subpopulations.

that of transformed cells displaying a metastatic phenotype after malignant transformation (Poste and Fidler, 1980). In effect, these evCTBs possess one major aptitude shared by all metastatic tumours, that of migration/invasion. In migratory and invasive evCTBs, as well as in malignant cells, invasion is not due to passive growth pressure but rather due to an active process that involves attachment to the basement membrane followed by detachment and proteolysis of the basement membrane before its penetration (Liotta, 1984; Bischof and Campana, 2000; Staff, 2001). However, the migratory and invasive capacities of invading evCTB cells are spatially and time regulated. Ultimately, cytotrophoblastic cells and malignant cells share similar behaviour resulting from similar capacities. These capacities enable either the accomplishment of successful embryo implantation and pregnancy progression when kept under control or the achievement of neoplastic and malignant transformation when such capacities are no longer kept under control.

Resemblance of the expression of key molecules implicated in proliferation, migration and invasive processes

The analogous behaviours of normal cytotrophoblast and cancer cells originate in part from their individual genetic programmes, and notably from their transcriptional and translational activities that result in the production of proteins. Thus, the road towards a better comprehension of the common characteristics shared by these cells must include the knowledge of genes and proteins similarly expressed by the two types of cells and which might play an important role in their analogous proliferative, migratory and invasive capacities. Amongst these genes and proteins are proto-oncogenes, growth factors, cell-surface receptors, enzymes, enzyme receptors and enzyme inhibitors, as well as various hormones and peptides. In addition, this comprehension must also include the elucidation of genes and proteins that could enable their immune escape.

Proto-oncogenes

Proto-oncogenes are normal cellular genes homologous to the viral oncogenes that induce cancer. Proto-oncogenes, once activated, become oncogenes that are also capable of inducing neoplasia. Activation occurs through various mechanisms such as mutation, gene amplification or chromosome rearrangement. Proto-oncogene products can be classified into cytokines, tyrosine kinases, receptors, G-proteins, cell-cycle regulators, DNA repair enzymes and transcription factors (Hesketh, 1995; Ruddon, 1995; Bischof and Campana, 2000). They are thus responsible for essential processes, including cell proliferation, migration and invasion. Proto-oncogenes play an important role in the aetiology of cancers, because their transcription is one of the first steps leading to malignant cell transformation (Bishop, 1987). Thus, it is noteworthy that several proto-oncogenes are similarly expressed by both normal trophoblasts and cancer cells. In the cancer catalogue, many oncogenes act by mimicking normal growth signalling in one way or another (Hahn and Weinberg, 2002). Similarly, several proto-oncogenes encoding growth factor receptors are expressed by trophoblast cells. The *c-erbB1* (*HER1*, *ERBB1* or *EGFR*) proto-oncogene is expressed exclusively by the cytotrophoblast in 4- to 5-week placenta and predominantly in the ST after 6 weeks of

gestation (Maruo and Mochizuki, 1987; Sugawara *et al.*, 1994; Maruo *et al.*, 1995). Owing to its mRNA expression pattern, it is thus not surprising that the cDNA sequence of human epidermal growth factor receptor (EGFR), the prototypical receptor tyrosine kinase (RTK), was isolated and characterized in 1984 both from normal placenta cells and from tumour cells (A431 epidermoid carcinoma cells) (Ullrich *et al.*, 1984; Gschwind *et al.*, 2004). This proto-oncogene encoded a 170-kDa transmembrane glycoprotein, the EGFR, which belongs to the *c-erbB* family of RTKs and which is involved in the pathogenesis of numerous tumours of different histological type, including breast cancers (Hynes and Lane, 2005). At least four other proto-oncogenes, namely *c-erbB2* (*HER2/neu*, *ERBB2*), *c-fms* (*CSF1R*), *c-met* (*MET*) and *c-kit* (*KIT*), encode RTKs and are expressed by both normal trophoblasts and cancer cells (Table I). *C-erbB2* is expressed by the evCTB (Fulop *et al.*, 1998) and codes for an RTK which, like the EGFR, is expressed by tumours of different histological types and is a target of cancer (immuno)therapy (Gschwind *et al.*, 2004). *C-fms* codes for the colony-stimulating factor receptor (CSF1R) and is expressed by the ST (Fulop *et al.*, 1998), whereas *c-met* is expressed by the cytotrophoblast (Kauma *et al.*, 1997) and codes for the hepatocyte growth factor/scatter factor (HGF/SF) receptor Met, a receptor that controls growth, invasion and metastasis in cancer cells (Birchmeier *et al.*, 2003). *C-kit* (*KIT*), which is expressed by villous trophoblast cells (Doneda *et al.*, 1997), codes for the stem cell factor (SCF) receptor that plays an important role in cell proliferation and cell migration (Kauma *et al.*, 1996).

Several other proto-oncogenes that do not code for RTKs are also expressed by normal trophoblast cells and tumour cells. *C-Abl* (*ABL1*) codes for a protein that displays serine/threonine kinase activity and that has been implicated in a range of cellular processes, including cell migration (Hantschel and Superti-Furga, 2004). *C-fos* (*FOS*), *c-jun* (*JUN*), *c-myc* (*MYC*) and *c-ets1* (*ETS1*) code for transcription factors and are all expressed by evCTBs (Goustin *et al.*, 1985; Quenby *et al.*, 1998; Bamberger *et al.*, 2004; Takai *et al.*, 2005), with the exception of *c-jun* that is also expressed by the villous trophoblasts (Bamberger *et al.*, 2004). It was recently demonstrated that the Fos protein is important in anchor cell invasion (Montell, 2005; Sherwood *et al.*, 2005) and that Fos is likely to contribute to cell invasion during both normal development of trophoblasts and pathological processes leading to metastases: Fos and Jun are expressed at the appropriate time and place in trophoblast cells so as to stimulate trophoblast invasion during the development of the placenta (Bischof, 2001). Fos, which forms heterodimers with Jun, also appears to contribute to tumour metastasis in at least some types of cancer: the expression of *c-fos* correlates with poor prognosis in squamous cell lung carcinomas (Volm *et al.*, 1993), and *c-fos* is expressed at higher levels in malignant prostate cancer than in benign prostatic hyperplasia (Aoyagi *et al.*, 1998). *C-myc* (*MYC*) transcripts display strong expression in evCTB cells of early placenta (Pfeifer-Ohlsson *et al.*, 1984): analyses of RNA from different periods of placental development show a 20- to 30-fold excess of *c-myc* transcription at 5 weeks as compared with terminal placenta. This ratio of transcription is within the same order of magnitude as that observed between the tumoral colon cell line COLO 320 HSR and normal colon cells (Alitalo *et al.*, 1983; Pfeifer-Ohlsson *et al.*, 1984; Sarkar *et al.*, 1986). This proto-oncogene is part of the post-receptor intracellular signalling pathway for the stimulation of cell proliferation by

Table I. Proto-oncogenes expressed by normal trophoblastic and malignant non-trophoblastic cells

Proto-oncogenes	Expression	
	Normal trophoblasts	Malignant tumours
<i>c-ras</i> (<i>RAS</i>) <i>c-kit</i> (<i>KIT</i>)	Villous cytotrophoblasts (vCTBs) (Sarkar <i>et al.</i> , 1986) vCTBs (Doneda <i>et al.</i> , 1997)	Colorectal (Downward, 2003) Breast (Crisi <i>et al.</i> , 2005) Testis (Nakai <i>et al.</i> , 2005)
<i>c-jun</i> (<i>JUN</i>)	Cytotrophoblast (CT), extravillous cytotrophoblasts (evCTBs) (Bamberger <i>et al.</i> , 2004)	Lung (Maeno <i>et al.</i> , 2006)
<i>c-met</i> (<i>MET</i>)	CT (Kauma <i>et al.</i> , 1997)	Kidney (Oya <i>et al.</i> , 2005) Colon (Resnick <i>et al.</i> , 2004) Gastric (Birchmeier <i>et al.</i> , 2003; Han <i>et al.</i> , 2005)
<i>c-fos</i> (<i>FOS</i>)	vCTB (Doneda <i>et al.</i> , 1997) ^a evCTB (Bamberger <i>et al.</i> , 2004)	Cervical (van Riggelen <i>et al.</i> , 2005) Breast (Calaf and Hei, 2004)
<i>c-myc</i> (<i>MYC</i>)	CT, evCTB (Pfeifer-Ohlsson <i>et al.</i> , 1984; Goustin <i>et al.</i> , 1985; Roncalli <i>et al.</i> , 1994)	Breast (Sirotkovic-Skerlev <i>et al.</i> , 2005)
<i>c-erb-B1</i> (<i>ERBB1</i> , <i>HER1</i>)	CT (before 6 weeks) Syncytiotrophoblast (ST) (after 6 weeks) (Maruo and Mochizuki, 1987; Hofmann <i>et al.</i> , 1992; Sugawara <i>et al.</i> , 1994 ^a ; Maruo <i>et al.</i> , 1995)	Endometrium (Geisler <i>et al.</i> , 2004) Breast (Gschwind <i>et al.</i> , 2004; Hynes and Lane, 2005) Ovary (Henic <i>et al.</i> , 2006)
<i>c-erb-B2</i> (<i>ERBB2</i> , <i>HER2</i>)	evCTB (Fulop <i>et al.</i> , 1998)	Breast (Hynes and Lane, 2005) Gastric (Pinto-de-Sousa <i>et al.</i> , 2002) Cervical (Nakano <i>et al.</i> , 1997) Ovary (Frutoso <i>et al.</i> , 2001)
<i>c-sis</i> (<i>SIS</i> , <i>PDGFB</i>)	evCTB (Goustin <i>et al.</i> , 1985)	Leukaemia (Romero <i>et al.</i> , 1986) Osteosarcoma (Graves <i>et al.</i> , 1984)
<i>c-fms</i> (<i>CSF1R</i>)	evCTB (Jokhi <i>et al.</i> , 1993) ST (Fulop <i>et al.</i> , 1998)	Liver (Yang <i>et al.</i> , 2004)
<i>c-Abl</i> (<i>ABL1</i>)	Trophoblasts (T) (Park <i>et al.</i> , 1992)	Leukaemia (Hantschel and Superti-Furga, 2004) Ovarian (Niyazi <i>et al.</i> , 2003)

^aExpression observed at the mRNA level.

a growth factor, and increased wild-type *MYC* expression occurs frequently in human cancers (Dang *et al.*, 2005). Immunoperoxidase studies have shown that *c-myc* transcripts are also translated in cytotrophoblasts (Maruo and Mochizuki, 1987). *C-ets1* (*ETS1*) is a downstream target of the HGF/SF pathway. Reciprocally, *ETS1* acts as a transcriptional factor for the *MET* gene (Paumelle *et al.*, 2002) and is thus implicated in cell proliferation and cell migration (Birchmeier *et al.*, 2003). This proto-oncogene is strongly expressed by evCTB cells during the first trimester of pregnancy (Takai *et al.*, 2005).

Apart from proto-oncogenes encoding transcription factors, two proto-oncogenes also expressed by both normal trophoblasts and malignant tumours, *c-sis* (*SIS*, *PDGFB*) and *c-ras* (*RAS*), code for proteins with different functions. The *c-sis* proto-oncogene encodes one of the two chains (the B-chain) constituting platelet-derived growth factor (PDGF). The *c-sis* proto-oncogene is transcribed in early placenta at levels comparable with transcription in human tumour (sarcoma) cell lines actively producing PDGF (Goustin *et al.*, 1985), and the maximal levels of *c-sis* transcripts are found in particularly active and invasive evCTB cells (Goustin *et al.*, 1985). The *c-ras* family of proto-oncogenes (*K-RAS*, *N-RAS* and *H-RAS*) codes for RAS proteins (small monomeric membrane-localized GTPases) that play an essential role in controlling the activity of several crucial signalling pathways that regulate cellular proliferation (Downward, 2003; Malumbres and Barbacid, 2003). *C-ras* transcripts were found in early villous trophoblast at 4 weeks after conception, and expression was not apparent at 8 weeks after conception (Sarkar *et al.*, 1986).

Finally, all these proto-oncogenes interact in a complex, only partially elucidated way to control cellular proliferation, migration and invasiveness, and it is remarkable that each type of trophoblast expresses a subtly different combination of proto-oncogenes (Quenby *et al.*, 1998). Moreover, it is noteworthy that several of those proto-oncogenes, including *c-erbB1*, *c-myc*, *c-ets1*, *c-sis* and *c-ras*, are preferentially expressed by trophoblast cells during the first weeks of pregnancy, a time at which the proliferative, migratory and invasive properties of these cells are at their peak.

Growth factors and their receptors

Growth factors and their receptors play a central role in cell proliferation. Indeed, normal cells require mitogenic growth signals (GSs) before they can move from a quiescent state into an active proliferative state. These signals are transmitted to the cell by transmembrane receptors that bind distinct classes of signalling molecules: diffusible growth factors, extracellular matrix (ECM) components and cell-to-cell adhesion/interaction molecules (Hanahan and Weinberg, 2000). It is now established that ectopic synthesis or excessive production of these classes of molecules may lead to the expression of a transformed phenotype. Interestingly, many of these growth factors and their receptors are similarly expressed by normal trophoblasts and malignant non-trophoblastic tumours (Tables II and III).

Among the growth factors expressed by both normal trophoblasts and malignant non-trophoblastic tumours are EGFs (Ladines-Llave *et al.*, 1991), CSF1 (Hamilton *et al.*, 1998), transforming growth

Table II. Growth factors expressed by normal trophoblastic and malignant non-trophoblastic cells

Growth factors	Expression	
	Normal trophoblasts	Malignant tumours
Epidermal growth factor (EGF)	Cytotrophoblast (CT) (late), syncytiotrophoblast (ST) (early) (Ladines-Llave <i>et al.</i> , 1991)	Endometrial carcinoma (Bellone <i>et al.</i> , 2005)
Platelet-derived growth factor (PDGF)-like Insulin-like growth factor-1 (IGF-1)	CT ^a (Goustin <i>et al.</i> , 1985) CT (early and late), ST (late) (Maruo <i>et al.</i> , 1995)	Gastric (Wada <i>et al.</i> , 1998) Liver ^a (Luo <i>et al.</i> , 2005) Gastric ^a (Zhao <i>et al.</i> , 2005)
IGF-2	CT ^a (Ohlsson <i>et al.</i> , 1989)	Liver ^a (Dong <i>et al.</i> , 2005) Breast (Giani <i>et al.</i> , 2002)
Colony-stimulating factor-1 (CSF1)	Extravillous cytotrophoblasts (evCTBs) (Hamilton <i>et al.</i> , 1998)	Breast (Sapi, 2004) Endometrial carcinoma (Smith <i>et al.</i> , 1995)
Vascular endothelial growth factor (VEGF)	evCTB (Clark <i>et al.</i> , 1996)	Thyroid (Vieira <i>et al.</i> , 2005)
Transforming growth factor (TGF)- β	ST (Dungy <i>et al.</i> , 1991)	Lung (Saji <i>et al.</i> , 2003)
Placental growth factor (PIGF)	Trophoblasts (T) (Torry <i>et al.</i> , 1999)	Breast (O'Brien <i>et al.</i> , 2003)

^aExpression observed at the mRNA level.**Table III.** Growth factor receptors expressed by normal trophoblastic and malignant non-trophoblastic cells

Growth factor receptors	Expression	
	Normal trophoblasts	Malignant tumours
Insulin receptors (IRs)	Cytotrophoblast (CT), syncytiotrophoblast (ST) (Jones <i>et al.</i> , 1993)	Prostate (Huang <i>et al.</i> , 2003)
Insulin-like growth factor (IGF)-IR	CT (early and late), ST (late) (Murata <i>et al.</i> , 1994)	Adrenocortical (Ilvesmaki <i>et al.</i> , 1993)
IGF-2R	Villous cytotrophoblast (vCTB) ^a (Ohlsson <i>et al.</i> , 1989)	Adrenocortical (Ilvesmaki <i>et al.</i> , 1993)
Corticotrophin-releasing factor (CRF)-R2	CT ^a (Florio <i>et al.</i> , 2000)	Central and peripheral nervous system (Reubi <i>et al.</i> , 2003)
Epidermal growth factor receptor (EGFR)	CT, ST (Maruo and Mochizuki, 1987; Hofmann <i>et al.</i> , 1992; Sugawara <i>et al.</i> , 1994 ^a ; Maruo <i>et al.</i> , 1995)	Breast (Gschwind <i>et al.</i> , 2004; Hynes and Lane, 2005) Ovarian (Henic <i>et al.</i> , 2006)
Hepatocyte growth factor receptor (HGFR)	CT (Kauma <i>et al.</i> , 1997)	Colon (Resnick <i>et al.</i> , 2004) Gastric (Birchmeier <i>et al.</i> , 2003; Han <i>et al.</i> , 2005)
Erythropoietin-R	vCTB, extravillous cytotrophoblasts (evCTBs), ST (Fairchild Benyo and Conrad, 1999)	Lung (Dagnon <i>et al.</i> , 2005)
Vascular endothelial growth factor receptor (VEGFR)-1 (Flt-1)	evCTB (Athanasziades <i>et al.</i> , 1998; Tseng <i>et al.</i> , 2006)	Breast (Acs <i>et al.</i> , 2002)
VEGFR-2 (KDR)		Breast (Meunier-Carpentier <i>et al.</i> , 2005)
Granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR)	vCTB, evCTB (Jokhi <i>et al.</i> , 1994)	Prostate (Rivas <i>et al.</i> , 1998)
G-CSFR	evCTB ^a (McCracken <i>et al.</i> , 1999)	Colon (Yang <i>et al.</i> , 2005)
ERBB2	evCTB (Fulop <i>et al.</i> , 1998)	Breast (Hynes and Lane, 2005) Gastric (Pinto-de-Sousa <i>et al.</i> , 2002) Cervical (Nakano <i>et al.</i> , 1997) Ovary (Frutuoso <i>et al.</i> , 2001)
CSF1R	evCTB (Jokhi <i>et al.</i> , 1993) ST (Fulop <i>et al.</i> , 1998)	Prostate (Ide <i>et al.</i> , 2002) Breast (Sapi, 2004) Liver (Yang <i>et al.</i> , 2004) Endometrial carcinoma (Smith <i>et al.</i> , 1995)
Platelet-derived growth factor (PDGF)-AAR	Trophoblasts (T) (Gurski <i>et al.</i> , 1999)	Breast (Carvalho <i>et al.</i> , 2005)

^aExpression observed at the mRNA level.

factor- α (TGF- α) (Horowitz *et al.*, 1993), TGF- β (Dungy *et al.*, 1991), insulin-like growth factor (IGF) (Maruo *et al.*, 1995), in particular IGF-2 (Ohlsson *et al.*, 1989), placental growth factor (PIGF) (Maglione *et al.*, 1991, 1993; Torry *et al.*, 1999), vascular endothelial growth factor (VEGF) (Clark *et al.*, 1996), erythropoietin (Conrad *et al.*, 1996) and PDGF-like protein (Goustin *et al.*,

1985). A trophoblast-derived growth factor has also been described as being similarly expressed by normal trophoblasts and malignant non-trophoblastic tumours (Sen-Majumdar *et al.*, 1986b): this peptide is actively expressed in cytotrophoblastic and ST cells in the human carcinoma cell line A431 and in the bladder and breast tumour cells (Bishayee *et al.*, 1984; Sen-Majumdar *et al.*,

1986a; Roy-Choudhury *et al.*, 1988). This 34-kDa protein is one of the most abundant molecules present on trophoblast membranes, especially during the first trimester of pregnancy. Its amino acid sequence resembles that of the calpactins, a family of proteins capable of binding calcium, phospholipids and actin. Finally, it is noteworthy that most of those growth factors, with the exception of TGF- β , are expressed by cytotrophoblast cells.

Among growth factor receptors expressed by both normal trophoblasts and malignant non-trophoblastic tumours, there are those encoded by proto-oncogenes which, once activated, become oncogenes capable of inducing neoplasia. These receptors, as described above, include EGFR/ERBB1, HER2/neu RTK/ERBB2, CSFR and HGF/SF receptor Met. Moreover, the trophoblast cells are rich in receptors for many other growth factors including the insulin receptor (Jones *et al.*, 1993), the IGF-I receptor (Murata *et al.*, 1994), the IGF-II receptor (Ohlsson *et al.*, 1989), VEGF receptors (VEGFR-1 or Flt-1 and VEGFR-2 or KDR) (Athanasias and Lala, 1998; Athanasias *et al.*, 1998; Chakraborty *et al.*, 2002; Tseng *et al.*, 2006), the erythropoietin receptor (Fairchild Benyo and Conrad, 1999), the granulocyte-macrophage (GM)-CSFR (Jokhi *et al.*, 1994), the granulocyte (G)-CSFR (McCracken *et al.*, 1999) and the PDGF receptor (Gurski *et al.*, 1999). Again, it is striking that a large majority of these receptors are expressed by cytotrophoblast cells.

Enzymes

Invasion and migration are complex processes, and their genetic and biochemical determinants remain incompletely understood. At the mechanistic level, they are closely allied processes, which justifies their association with one another as representing a common function of both normal and cancer cells. The two processes utilize similar operational strategies involving changes in physical coupling of cells to their microenvironment and activation of extracellular proteases. Many proteases, protease receptors and protease inhibitors are similarly expressed by both normal trophoblasts and malignant cells (Table IV). These proteases include several members of the family of matrix metalloproteinases (MMPs) (Bischof *et al.*, 2000). MMPs, also called matrixins, are a family of at least 17 human zinc-dependent endopeptidases collectively capable of degrading essentially all components of the ECM. Normal trophoblasts and cancer cells express (i) MMP-2 (also called gelatinase A) and MMP-9 (also called gelatinase B) (Bjorn *et al.*, 2000; Isaka *et al.*, 2003), which digest collagen type IV (the major constituent of basement membranes) and denatured collagen (gelatine); (ii) MMP-11 (also called stromelysin-3), which digests collagen; and (iii) a membrane-bound MMP, membrane-type MMP-1 (MT-MMP-1), which is thought to activate progelatinase A. Most MMPs are secreted as inactive proenzymes that become activated in the extracellular compartments. In addition to MT-MMPs, several enzymes are capable of activating these proenzymes, the most prominent being plasmin. The latter enzyme is activated from plasminogen by the urokinase plasminogen activator (uPA), which is also secreted by normal trophoblastic and malignant non-trophoblastic cells and is involved in the invasive behaviour of these cells. Both trophoblasts and cancer cells also express the uPA receptor (Zini *et al.*, 1992), which can bind active uPA and localize proteolysis to the leading edge of migrating cells (Estreicher *et al.*, 1990; Roldan *et al.*, 1990; Strickland and Richards,

1992). The activity of the plasminogen activator is inhibited by the plasminogen activator inhibitor (PAI-1), which is also expressed by both trophoblasts and malignant tumours. Moreover, the activity of MMPs in the extracellular space is inhibited by the tissue inhibitors of metalloproteinases (TIMPs) that bind specifically to the highly conserved zinc-binding site of active MMPs at molar equivalence. The TIMP gene family consists of four structurally related members, TIMP-1, TIMP-2, TIMP-3 and TIMP-4, and both normal trophoblastic and malignant non-trophoblastic cells express TIMP-1. Other enzymes such as heparan sulphate-degrading endoglycosidase, similarly referred to as heparanase, are expressed by cytotrophoblasts (Klein and Von Figura, 1976; Haimov-Kochman *et al.*, 2002), and the expression of heparanase correlates with the metastatic behaviour of cancer cells (Parish *et al.*, 1987; Nakajima *et al.*, 1988; Friedmann *et al.*, 2000). In addition, two protease receptors are also expressed by normal trophoblasts and cancer cells: the protease-activated receptor (PAR) (O'Brien *et al.*, 2003) and the receptor for thrombin, a serine protease (Even-Ram *et al.*, 1998). Taken together, these data show that trophoblasts and malignant cells possess many similar components implicated in molecular circuitries aimed at degrading the ECM.

Various (glyco)protein hormones, peptides and receptors

Various hormones, peptides and receptors similarly expressed by normal trophoblasts and malignant cells are quite impressive (Table V), especially when bearing in mind that many of those molecules may have a direct or indirect impact on the proliferative, migratory and invasive properties of these cells. Amongst these hormones, peptides and receptors are the following: a growth hormone variant (hGH-V) (Scippo *et al.*, 1993), human placental lactogen (HPL) (Sasagawa *et al.*, 1987), prolactin (PRL) (Kasai *et al.*, 1982), urocortin (Clifton *et al.*, 2000), Met-enkephalin (Sastry *et al.*, 1980), β -endorphin (Laatikainen *et al.*, 1987), dynorphins (DYN) (Ahmed *et al.*, 1992), somatostatin (Watkins and Yen, 1980), thyrotrophin-releasing hormone (TRH) (Bajoria and Babawale, 1998), GnRH (Chou *et al.*, 2004), inhibin (Shih and Kurman, 1999), activin (Caniggia *et al.*, 1997), follistatin (Petraglia *et al.*, 1994), neuropeptide Y (NPY) (Petraglia *et al.*, 1989), renin (Tomita *et al.*, 1987; Egan *et al.*, 1988), oxytocin (Chibbar *et al.*, 1993), relaxin (Bryant-Greenwood *et al.*, 1987), leptin (O'Brien *et al.*, 1999; Castellucci *et al.*, 2000), tumour necrosis factor- α (TNF- α) (Haynes *et al.*, 1993), ACTH (Saijonmaa *et al.*, 1988), corticotrophin-releasing factor (CRF) (Saijonmaa *et al.*, 1988), their receptors CRF-R1 and CRF-R2 (Florio *et al.*, 2000) and a receptor for leukaemia inhibitory factor (LIF) (Sharkey *et al.*, 1999). Recent studies have shown that molecules such as pro-early placenta insulin-like peptide (pro-EPIL), a novel peptide involved in the motility and invasiveness of cancer cells (Bellet *et al.*, 1997a; Brandt *et al.*, 2002), and metastin, a peptide encoded by metastasis suppressor gene *KiSS-1* (Ohtaki *et al.*, 2001; Bilban *et al.*, 2004), are also produced by both normal trophoblastic and cancer cells.

Tumour-associated antigens

An overview of the traits common to both normal trophoblasts and cancer cells cannot overlook tumour-associated antigens (TAAs) expressed by both types of cells (Table VI), even though the implication of these antigens in the comparable behaviour of such

Table IV. Enzymes, enzyme receptors and enzyme inhibitors expressed by normal trophoblastic and malignant non-trophoblastic cells

Enzymes, enzyme receptors and enzyme inhibitors	Expression	
	Normal trophoblasts	Malignant tumours
Membrane-type matrix metalloproteinase-9 (MT-MMP-9) (gelatinase B)	Cytotrophoblast (CT) (Isaka <i>et al.</i> , 2003; Cohen <i>et al.</i> , 2006b)	Ovarian ^a (Hu <i>et al.</i> , 2004)
Heparanase	CT (Haimov-Kochman <i>et al.</i> , 2002)	Breast (Cohen <i>et al.</i> , 2006a) Pancreas (Schoppmeyer <i>et al.</i> , 2005)
Thrombin receptor	CT (Even-Ram <i>et al.</i> , 1998)	Breast (Even-Ram <i>et al.</i> , 1998)
Urokinase plasminogen activator (uPA)	Extravillous cytotrophoblasts (evCTBs) (Floridon <i>et al.</i> , 1999)	Bladder (Champelovier <i>et al.</i> , 2002) Breast (Kim <i>et al.</i> , 1997) Gastric (Iwamoto <i>et al.</i> , 2005)
uPA receptor	evCTB (Floridon <i>et al.</i> , 1999)	Gastric ^a (Iwamoto <i>et al.</i> , 2005) Breast (Kim <i>et al.</i> , 1997)
Tissue inhibitor of metalloproteinase-1 (TIMP-1)	evCTB (Huppertz <i>et al.</i> , 1998)	Breast ^a (Nakopoulou <i>et al.</i> , 2002) Ovarian ^a (Hu <i>et al.</i> , 2004) Colon ^a (Pesta <i>et al.</i> , 2005)
MT-MMP-1	evCTB (Nawrocki <i>et al.</i> , 1996)	Colon ^a (Okada <i>et al.</i> , 1995)
Protease-activated receptor (PAR)	evCTB (O'Brien <i>et al.</i> , 2003)	Breast (Boire <i>et al.</i> , 2005)
MT-MMP-11	evCTB (Maquoi <i>et al.</i> , 1997; Cohen <i>et al.</i> , 2006b)	Gastric (Deng <i>et al.</i> , 2005)
MT-MMP-2	evCTB ^a (Bjorn <i>et al.</i> , 2000)	Ovarian ^a (Hu <i>et al.</i> , 2004)
	evCTB (Isaka <i>et al.</i> , 2003; Cohen <i>et al.</i> , 2006b)	Colon ^a (Pesta <i>et al.</i> , 2005)
Plasminogen activator inhibitor (PAI-1)	Trophoblasts (T) (Zini <i>et al.</i> , 1992)	Colorectal ^a (Sakakibara <i>et al.</i> , 2005) Gastric ^a (Iwamoto <i>et al.</i> , 2005)

^aExpression observed at the mRNA level.

cells is unclear. The prototypic TAA expressed by both trophoblasts and cancer cells is the beta subunit of hCG β . hCG is a glycoprotein hormone composed of two non-covalently linked molecules, the alpha subunit (hCG α) and the beta subunit (hCG β). Alpha and beta subunits of hCG are produced by ST cells and secreted into the maternal circulation preferentially in the form of the α/β dimer that constitutes hCG (Ozturk *et al.*, 1988). hCG is found in the blood of pregnant women at 6–8 days after fertilization (Tyrey, 1982), but hCG β mRNA is already detectable at the 8-cell stage (Bonduelle *et al.*, 1988). The free hCG β subunit is also produced by numerous non-trophoblastic malignant tumours of different histological types, including bladder, pancreatic and cervical carcinomas (Marcillac *et al.*, 1992). Indeed, the similarity between normal trophoblastic cells and malignant non-trophoblastic cells is particularly striking at the level of hCG β gene expression: the beta subunit of hCG, which is comprised of 145 amino acid residues, is encoded by four non-allelic *CG* beta (*CG* β) genes. Type I *CG* β allelic genes beta-7 and beta-6 possess a GCC codon corresponding to an alanine at position 117 of hCG β , whereas type II *CG* β genes beta-8, beta-5 and beta-3 and its allele beta-9 possess a GAC codon corresponding to an aspartic acid at the same position (Figure 2). In normal trophoblast, hCG β is encoded by type II *CG* β genes, whereas normal non-trophoblastic tissues of a different histological origin (breast, prostate, skeletal muscle, bladder, adrenal glands, thyroid, colon and uterine) express only type I *CG* β genes. In contrast, non-trophoblastic tumours of differing histological origins, including breast, bladder, prostate and thyroid cancers, express type II *CG* β genes. Experiments performed on tumour tissues and their normal counterparts have confirmed that the malignant transformation of non-trophoblastic cells is associated with the expression of type II *CG* β genes expressed by normal trophoblastic cells (Bellet *et al.*, 1997b). These observations are a salient illustration of the exquisite

similarity between normal trophoblast and malignant non-trophoblastic tumours in terms of the expression of certain genes.

Apart from the prototypic TAA hCG β , several other TAAs are also expressed by trophoblasts, including prostate-specific antigen (PSA), an antigen overexpressed by prostate cancers (Malatesta *et al.*, 2000), osteopontin (OPN) (Briese *et al.*, 2005a) and CEACAM1, a member of the carcinoembryonic antigen (CEA) family (Bamberger *et al.*, 2001). Moreover, the pregnancy-specific β -glycoprotein (PS- β G) family is characteristic of trophoblasts (Lei *et al.*, 1992) and contains molecules displaying close homologies to CEA (Oikawa *et al.*, 1989; Leslie *et al.*, 1990). In addition, recently identified genes from the melanoma antigen (MAGE), G antigen (GAGE) and P antigen (PAGE) families that encoded tumour-specific shared antigens expressed by either melanomas or a prostate cancer cell line are also expressed in the placenta (Chen *et al.*, 1998; De Backer *et al.*, 1999; Kwon *et al.*, 2005).

Taken together, these data indicate that numerous genes and proteins are similarly expressed by normal trophoblastic cells and malignant non-trophoblastic cells. In line with that observation, a recent study using DNA microarrays showed that cancer cells overexpress genes that are preferentially expressed in only one type of normal tissue, such as placenta. On the basis of the latter observations, it was suggested that the ability to overexpress genes normally preferentially expressed in tissues other than those of the cancer's origin is a general property of cancer cells and that this capacity is of major importance in determining the behaviour of the cancer, including its metastatic potential (Lotem *et al.*, 2005).

Similar mechanisms of proliferation

Several comparable mechanisms may explain the high proliferative capacity of both trophoblastic and cancer cells. Amongst them, and as shown by recapitulation of the many key molecules

Table V. Various (glycoprotein) hormones, peptides and receptors expressed by normal trophoblastic and malignant non-trophoblastic cells

(Glyco) protein hormones, peptides, receptors	Expression	
	Normal trophoblasts	Malignant tumours
Somatostatin	Cytotrophoblast (CT) (Watkins and Yen, 1980)	Pancreas (Tamiolakis <i>et al.</i> , 2005)
Metastin	CT (Bilban <i>et al.</i> , 2004)	Breast (Martin <i>et al.</i> , 2005)
Activin A	CT (Caniggia <i>et al.</i> , 1997)	Endometrium ^a (Otani <i>et al.</i> , 2001) Liver (Wagner <i>et al.</i> , 2004)
Neuropeptide Y (NPY)	CT (Petraglia <i>et al.</i> , 1989)	Pancreas (Waeber <i>et al.</i> , 1995) Pituitary (Grouzmann <i>et al.</i> , 1998)
Relaxin	CT (Bryant-Greenwood <i>et al.</i> , 1987)	Breast (Tashima <i>et al.</i> , 1994)
Corticotrophin-releasing factor (CRF)	CT (Saijonmaa <i>et al.</i> , 1988)	Endometrium ^a (Florio <i>et al.</i> , 2003) Bronchial carcinoid (Suda, 1994)
Pro-early placenta insulin-like peptide (Pro-EPIL)	Villous cytotrophoblast (vCTB) (Bellet <i>et al.</i> , 1997a)	Breast (Brandt <i>et al.</i> , 2002)
CRF-R2	CT ^a (Florio <i>et al.</i> , 2000)	Central and peripheral nervous system (Reubi <i>et al.</i> , 2003)
Leukaemia inhibitory factor (LIF-R)	vCTB–extravillous cytotrophoblasts (evCTBs) (Sharkey <i>et al.</i> , 1999)	Prostate (Garcia-Tunon <i>et al.</i> , 2005)
GnRH	evCTB (Chou <i>et al.</i> , 2004)	Ovary (Savarese <i>et al.</i> , 2002) Ovarian (Grundker and Emons, 2003) Breast (Grundker <i>et al.</i> , 2002) Endometrium (Grundker <i>et al.</i> , 2002)
Leptin	evCTB (Castellucci <i>et al.</i> , 2000)	Breast (O'Brien <i>et al.</i> , 1999; Somasundar <i>et al.</i> , 2004)
Human placental lactogen (HPL) or human chorionic somatomammotropin (HCS)	evCTB (Sasagawa <i>et al.</i> , 1987)	Breast (Bonnetterre <i>et al.</i> , 1990)
Methionine enkephalin	Villous placenta (Sastry <i>et al.</i> , 1980)	Thyroid, pituitary, carcinoid (Bostwick <i>et al.</i> , 1987)
Inhibin	Syncytiotrophoblasts (STs) (Shih and Kurman, 1999)	Ovary (Yamashita <i>et al.</i> , 1997) Breast (Shih and Kurman, 1999)
Follistatin	ST (Petraglia <i>et al.</i> , 1994)	Endometrium (Ciarmela <i>et al.</i> , 2004)
Prolactin (PRL)	ST (Kasai <i>et al.</i> , 1982)	Colon (Otte <i>et al.</i> , 2003)
Thyrotrophin-releasing hormone (TRH)	ST (Bajoria and Babawale, 1998)	Melanoma (Ellerhorst <i>et al.</i> , 2004)
Beta endorphin	ST (Laatikainen <i>et al.</i> , 1987)	Breast (Nesland <i>et al.</i> , 1988)
Growth hormone (GH)	ST (Scippo <i>et al.</i> , 1993)	Breast (Ahmed <i>et al.</i> , 1992; Mol <i>et al.</i> , 1995; Laban <i>et al.</i> , 2003)
Urocortin	ST (Clifton <i>et al.</i> , 2000)	Prostate (Arcuri <i>et al.</i> , 2002)
TNF- α	ST (Haynes <i>et al.</i> , 1993)	Ovary (Kulbe <i>et al.</i> , 2005)
CRF-R1	ST ^a (Florio <i>et al.</i> , 2000)	Central and peripheral nervous system (Reubi <i>et al.</i> , 2003)

^aExpression observed at the mRNA level.

Table VI. Tumour-associated antigens (TAAs) expressed by normal trophoblastic and malignant non-trophoblastic cells

TAAs	Expression	
	Normal trophoblasts	Malignant tumours
CEACAM1	Extravillous cytotrophoblasts (evCTBs) (Bamberger <i>et al.</i> , 2001)	Colorectal (Nittka <i>et al.</i> , 2004)
Osteopontin (OPN)	evCTB (Briese <i>et al.</i> , 2005b)	Ovary (Kim <i>et al.</i> , 2002) Breast (Das <i>et al.</i> , 2004)
hCG- β	Syncytiotrophoblast (ST) (Yoshida, 2005)	Gonadal and non-gonadal (Marcillac <i>et al.</i> , 1992)
Prostate-specific antigen (PSA)	ST (Malatesta <i>et al.</i> , 2000)	Prostate (Hood <i>et al.</i> , 2005)

expressed by the two types of cells, many are growth factors or growth factor receptors, suggesting that autocrine and paracrine growth might be important mechanisms in their proliferation.

Autocrine and paracrine growth

Although most soluble mitogenic growth factors are made up of one cell type to stimulate the proliferation of another (the process of heterotypic signalling), many cells acquire the ability to synthesize

growth factors to which they are responsive, creating a positive feedback signalling loop often termed autocrine stimulation. Autocrine signalling (production of, and response to, a ligand by the same cell) is a similar mechanism of signal transduction in normal physiological processes. During tumorigenesis, misregulated autocrine signalling can render cancer cells less dependent on survival and growth factors from surrounding tissues. Several autocrine loops are common features of both trophoblastic and cancer cells, and notably the EGF/EGFR loop (Hofmann *et al.*, 1992; Maruo *et al.*,




Figure 2. Organization of the CGβ/LHβ gene cluster and expression of human CGβ genes that code for the hCGβ subunit, a prototypic tumour-associated antigen. Normal trophoblastic and malignant non-trophoblastic cells express type II CGβ genes encoding the hCGβ subunit with an aspartic acid residue (ASP) at position 117. Normal non-trophoblastic cells express type I CGβ genes encoding the hCGβ subunit with an alanine residue (ALA) at position 117. LHβ: gene encoding the beta subunit of human lutropin.

1995; Petraglia *et al.*, 1996), the IGF-2/IGF-2R loop (Ohlsson *et al.*, 1989), the CSF1/CSF1R loop (Hamilton *et al.*, 1998), the PDGF/PDGFR loop (Goustin *et al.*, 1985) and the VEGF/VEGFR (Flt-1 and KDR) loop (Ahmed *et al.*, 1995; Athanassiades and Lala, 1998; Athanassiades *et al.*, 1998). The engagement of RTKs with growth factors such as EGF or IGF-2 promotes the activation of mitogen-activated protein kinase (MAPK) signalling (Lewis *et al.*, 1998). Amongst the numerous MAPKs that are classified into four different families, protein kinases belonging to the extracellular-regulated kinase (ERK) family are the MAPKs predominantly activated by growth factors. A highly complex network of protein kinases regulates the activity of MAPKs through sequential phosphorylations at critical Ser, Thr and Tyr residues. Proteins of the MAPK kinase kinase (MAPKKK) family such as Raf or MEKK phosphorylate MAPK kinases (MAPKKs) including MEKs. The MAPKKs then activate the four major families of MAPKs including the ERK family. ERKs have been shown to play an important role in growth-factor-dependent regulation of trophoblast growth and migration (Pollheimer and Knofler, 2005). In the placenta, the expression of ERK1 and ERK2 was detected in vCTBs, but their active phosphorylated forms were only present until the 12th week of gestation, suggesting a predominant role during early pregnancy (Kita *et al.*, 2003).

Apart from MAPK signalling, a second pathway downstream from RTKs involves phosphatidylinositol 3'-kinase (PI3K) and AKT and is an important regulator of cell proliferation and survival (Vivanco and Sawyers, 2002). Phosphorylated RTKs interact with p85 subunits of PI3K and recruit the enzyme to the membrane, whereas GTPases activate PI3K through binding of its p110 subunit. At the membrane, PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) and thereby converts PIP2 to phosphatidylinositol(3,4,5)triphosphate (PIP3), which activates the serine/threonine protein kinases AKT and PDK1. AKT/kinase B (PKB), a serine/threonine protein kinase that possesses three isoforms, phosphorylates a plethora of other target proteins that control proliferation, survival and cell size (Toker and Yoeli-Lerner, 2006), whereas PDK1 phosphorylates different protein kinase C (PKC) subunits. PKC and Ca/calmodulin-dependent

kinase II (CaMKII) are also controlled through the PIP3-mediated increase in cytosolic Ca²⁺ levels. PIP3 levels are tightly regulated by lipid phosphatases such as phosphatase and tensin (PTEN) homologue converting PIP3 to PIP2 (Vivanco and Sawyers, 2002). The activation of the PI3K/AKT pathway and loss-of-function mutations of PTEN, which acts as a tumour suppressor, have been noted in a wide range of cancers (Cully *et al.*, 2006). One of the critical targets of AKT is mTOR that plays a crucial role in PI3K-mediated oncogenesis (Vivanco and Sawyers, 2002). The kinase mTOR controls cell-cycle progression and cell size/mass through phosphorylation of proteins controlling protein translation (Fingar and Blenis, 2004). The activation of PI3K also plays a role in migration/invasion, for example, during IGF-I-induced migration of vascular smooth muscle cells (Duan *et al.*, 2000). PI3K also plays a crucial role in growth-factor-mediated trophoblast migration. The activation of PI3K with specific peptides resulted in increased motility of SGHPL-5 evCTB cells, whereas the inhibition of PI3K reduced basal and HGF-induced migration (Cartwright *et al.*, 2002). The integrated action of PI3K and ERK in EGF-stimulated phosphorylation and migration of HTR-8/SVneo evCTB cells was also demonstrated (Qiu *et al.*, 2004a,b).

Growth factors can also activate focal adhesion kinase (FAK), a widely expressed non-receptor protein tyrosine kinase that has a growth/migration-promoting role. The activation of FAK is achieved by phosphorylation at different amino acid residues, in particular by phosphorylation at Tyr-397, and FAK activity was shown to be associated with tumour progression of cancer cells towards a malignant phenotype (Gabarra-Niecko *et al.*, 2003). It is thus noteworthy that the phosphorylated form of the kinase was predominantly detected in interstitial cytotrophoblasts and was more abundant during the first weeks of pregnancy, colocalizing with the extravillous trophoblast markers MMP-2 and α5 integrin. In addition, the down-regulation of FAK reduced the outgrowth/migration of villous explant cultures and diminished the invasion of isolated cytotrophoblasts through Matrigel-coated chambers (Ilic *et al.*, 2001; MacPhee *et al.*, 2001). FAK also has an impact on activities of Rho proteins, a family (RhoA, Rac1, Cdc 42) of particular GTPases regulating diverse biological processes such as

cell cycle, cell–cell/focal adhesions, polarization and cell migration (Hall, 1998; Goode *et al.*, 2000). The downstream effectors of Rho include p21-activated kinase (PAK), which cross-talks to the MAPK pathway by modulating Raf and Rho-associated, coiled-coil containing protein kinase (ROCK). The functionality of the RhoA–ROCK signalling cascade has also been suggested during trophoblast migration. Experiments based on presumptive extravillous trophoblast obtained after plating of minced first-trimester placental fragments showed that the treatment of these cells with selective Rho and ROCK inhibitors reduced spreading and migration through fibronectin-coated filters (Shiokawa *et al.*, 2002).

The effects of autocrine signalling can also be amplified by paracrine signalling between neighbouring homotypic and heterotypic cells. Within normal tissue such as the placenta, cells are also instructed to grow by their neighbours (paracrine signals) or via systemic (endocrine) signals. Cell-to-cell growth signalling is likely to operate in the vast majority of human tumours as well; virtually, all are composed of several distinct cell types that appear to communicate via heterotypic signalling (Hanahan and Weinberg, 2000). Amongst paracrine loops common to both trophoblasts and cancer cells is the HGF/HGFR (Met) loop: cytotrophoblasts express Met (HGFR) (Saito *et al.*, 1995), whereas mesenchymal cells within the stromal cores of chorionic villi produce HGF (Kauma *et al.*, 1997). The binding of HGF to Met leads to the phosphorylation of two C-terminal tyrosine residues and the generation of a multidocking site. These phosphoryrosines mediate high-affinity interactions with Src homology 2 (SH2) domains of many proteins, including the p85 subunit of PI3K that can then transduce signals to downstream targets (Birchmeier *et al.*, 2003). HGF/SF signals induce proliferative and anti-apoptotic responses in various cell types. In cancer cells, HGF/SF signals control growth, invasion and metastasis. Similarly, HGF/SF and Met provide essential signals for survival and proliferation of trophoblasts (Birchmeier *et al.*, 2003). HGF also increases trophoblast mobility and invasion: experiments performed with the extravillous trophoblast cell line SGHPL-4 demonstrate that the PI3K signalling pathway is involved in basal trophoblast mobility and that both MAPK and PI3K signalling pathways are important in HGF-stimulated mobility (Cartwright *et al.*, 2002). Another paracrine loop common to both normal trophoblasts and neoplasia is the VEGF/VEGFR loop. VEGFs are crucial regulators of vascular development during embryogenesis (vasculogenesis) as well as of blood-vessel formation (angiogenesis) of both normal tissues and malignant tumours in the adult. In a broader perspective, the VEGFRs induce cellular processes that are common to many growth-factor receptors, including cell migration, survival and proliferation (Olsson *et al.*, 2006). Several reports indicate that cytotrophoblasts in cell columns and in the placental bed express the VEGF receptor-1 (VEGFR-1 or Flt-1), one of the three VEGF RTKs, and that VEGFA (usually called VEGF) itself, one of the five members of the VEGF family, is expressed by cytotrophoblasts as well as by fetal macrophages in chorionic villi and by maternal macrophages in the uterine wall (Ahmed *et al.*, 1995; Clark *et al.*, 1996; Shiraiishi *et al.*, 1996). Moreover, VEGFR-1 also binds placenta growth factor (PlGF), another member of the VEGF family expressed by normal trophoblasts and by cancer cells. In extravillous trophoblast, it has been reported that VEGFA and PlGF stimulate proliferation but not migration or invasiveness of these cells (Athanasopoulos and

Lala, 1998; Athanasopoulos *et al.*, 1998). Thus, evCTB, via VEGFR-1, could respond in either a paracrine or an autocrine fashion to VEGFA and PlGF (Zhou *et al.*, 1997b). The VEGFR-1 tyrosine kinase exhibits all the conserved motifs that are required for kinase activity. Several VEGFR-1 tyrosine phosphorylation sites and their potential interacting partners, including the p85 subunit of PI3K, have been described (Olsson *et al.*, 2006). Indeed, the level of phosphorylation of VEGFR-1 in response to VEGFA is low (Waltenberger *et al.*, 1994; Seetharam *et al.*, 1995). However, a particular feature of the VEGFA ligand is the dramatic up-regulation of its expression levels under hypoxic conditions. Hypoxia, a condition that may affect both evCTB and cancer cells, allows the stabilization of hypoxia-inducible factors (HIFs) that bind to specific promoter elements that are present in the promoter region of VEGFA (Pugh and Ratcliffe, 2003). Similarly, the expression of VEGFR-1 is directly regulated by HIFs (Gerber *et al.*, 1997).

Taken together, these data show that several autocrine and paracrine loops can be used by normal proliferative trophoblasts and by cancer cells to expand in number.

Evasion of apoptosis

The ability of cell populations to expand in number is determined not only by the rate of cell proliferation but also by the rate of cell attrition. Programmed cell death (apoptosis) represents a major source of this attrition. Numerous observations indicate that the apoptotic program is present in latent form in virtually all cell types throughout the body. The apoptotic machinery can be broadly divided into two classes of components, sensors and effectors. The sensors are responsible for monitoring the extracellular and intracellular environment for conditions of normality or abnormality that influence whether a cell should live or die. These signals regulate the second class of components, which function as effectors of apoptotic death (Hanahan and Weinberg, 2000). The sensors include cell-surface receptors that bind survival or death factors. Examples of these ligand/receptor pairs similarly expressed by trophoblasts and cancer cells are the survival signals conveyed by IGF-1/IGF-2 through the receptor IGF-1R (Lotem and Sachs, 1996; Butt *et al.*, 1999). Signalling through the IGF receptor has been shown to have a potent survival function and protects cells from various apoptotic stimuli (Butt *et al.*, 1999). The IGF pathway is unique in that, upon ligand binding and receptor autophosphorylation, insulin receptor substrate-1 (IRS-1) associates with IGF-1R. Tyrosine phosphorylation of IRS-1 in turn leads to the binding and activation of PI3K. The phosphorylation of inositol membrane lipids at the 3' position by PI3K is a critical step in the IGF-IR signalling pathway. Many kinases have been identified that associate with these 3'-phosphorylated membrane lipids and subsequently participate in the kinase signalling cascade. AKT, one of the kinases in this activation cascade, has a distinct function in promoting cell survival by phosphorylating and blocking the proapoptotic activity of proteins such as BCL2-antagonist of cell death (BAD). Apart from the PI3K-AKT-mTOR system, another downstream network of IGF-1R includes the RAF-MAPK system. The activation of these pathways stimulates proliferation, as underlined previously, and inhibits apoptosis. In cancer cells, several model systems have provided evidence that IGF-1 receptor activation increases not only proliferation but also

metastasis (Khandwala *et al.*, 2000; Pollak *et al.*, 2004). In trophoblast cells, it remains to be determined whether the activation of this receptor is primarily involved in proliferation, or rather, in the invasive capacities of these cells (Chakraborty *et al.*, 2002).

Similar mechanisms of migration and invasion

A striking similarity between cytotrophoblasts and neoplastic cells lies in their proliferative capacities. Additional cellular changes enable these cells to acquire migratory and invasive capacities so as to undergo transformation into either invasive evCTB, 'physiological metastasis', or malignant cells capable of metastasizing. To accomplish this transformation, the two types of cells utilize similar operational strategies, involving changes in the physical coupling of cells to their microenvironment and activation of extracellular proteases. As might be expected, in addition to producing proteinases that degrade the ECM, all highly invasive cells, including evCTB cells, share an altered adhesion molecule phenotype (Plantefaber and Hynes, 1989; Albelda *et al.*, 1990; Giancotti and Ruoslahti, 1990; Behrens *et al.*, 1993; Oka *et al.*, 1993).

Altered adhesion molecule phenotype

Several classes of proteins involved in the tethering of cells to their surroundings in a tissue are altered in cells possessing invasive or metastatic functions (Hanahan and Weinberg, 2000). The affected proteins include integrins, which link cells to ECM substrates. Integrins are heterodimeric receptors resulting from combinatorial expression of various α - and β -receptor subunits. These combinations lead to over 22 different integrin subtypes that have distinct substrate preferences. Other affected proteins belong to two different classes of cell–cell adhesion molecules (CAMs): the first class comprises cadherins, which mediate Ca^{2+} -dependent cell–cell adhesion, and the second class comprises various adhesion receptors belonging to the immunoglobulin family. Notably, all of these cell adhesion receptors convey regulatory signals to the cell (Aplin *et al.*, 1998).

In effect, trophoblasts change their adhesive properties during invasion. This occurs *in vivo* when the cytotrophoblast cells leave their basement membrane to differentiate into evCTB cells. The invasion of cytotrophoblasts leads to a decrease in the expression of adhesion receptors characteristic of cytotrophoblast stem cells and an increase in the expression of adhesion receptors that are characteristic of vascular cells. Besides enabling cytotrophoblasts that line the maternal vessels to masquerade as vascular cells, these receptors also improve the ability of extravillous trophoblastic cells to invade the uterine wall (Campbell *et al.*, 1995; Damsky and Fisher, 1998). Human cytotrophoblast stem cells within the villi express $\alpha 6 \beta 4$ integrin, a receptor for epithelial laminin. As they leave the basement membrane, they down-regulate the $\alpha 6 \beta 4$ integrin and begin to express the $\alpha 5 \beta 1$ integrin, a fibronectin receptor, and move into the fibronectin-rich matrix of the invasive cell columns (Redman, 1997). Within the uterine wall, they produce $\alpha 1 \beta 1$ integrin, a receptor for laminin and type IV collagen that contributes to the acquisition of an invasive phenotype by evCTBs (Damsky *et al.*, 1992, 1994). Cytotrophoblasts also express other integrins in response to the acquisition of invasiveness. In particular, cytotrophoblasts express αv integrins that seem to be important in the formation of some types of metastatic

tumours (Redman, 1997). Integrin $\alpha v \beta 5$ is characteristic of vCTBs, whereas $\alpha v \beta 6$ is only expressed on the cells at the base of the invasive cell columns. evCTBs in the uterine interstitium and maternal vasculature, like endothelial cells during angiogenesis, express integrin $\alpha v \beta 3$. Because the treatment of isolated cytotrophoblasts with antibody to integrin $\alpha v \beta 3$ significantly hampers their invasion, it was suggested that increased expression of this integrin by evCTB *in vivo* stimulates their motility and invasiveness (Zhou *et al.*, 1997b). In a similar way, changes in integrin expression are also evident in invasive and metastatic cells. During their migration, invading and metastasizing cancer cells experience changing tissue microenvironments that can present novel matrix components. Accordingly, successful colonization of these new sites (both local and distant) requires adaptation, which is achieved through shifts in the spectrum of integrins displayed by the migrating cells. Indeed, carcinoma cells facilitate invasion by shifting their expression of integrins from those that favour ECM present in normal epithelium to other integrins, including $\alpha v \beta 3$ that preferentially bind the degraded stromal components produced by extracellular proteases. $\alpha v \beta 3$ is the integrin expressed by evCTBs in the uterine wall, and studies have implicated integrin $\alpha v \beta 3$ in the transition of cancer cells to an invasive phenotype *in vivo* (Albelda *et al.*, 1990; Felding-Habermann *et al.*, 1992; Irish *et al.*, 2006), emphasizing the fact that normal cytotrophoblasts and cancer cells perform similar integrin switching to acquire invasive capacities. Indeed, integrin ligation induces a complex network of signalling pathways to control cell migration (Guo and Giancotti, 2004). Integrin binding to ligands activates FAK, which binds and activates multiple signalling proteins. FAK autophosphorylation causes it to bind to adaptor growth-factor-receptor-bound protein 2 (GRB2) and to activate another small G protein, RAS. FAK activation also promotes SRC-dependent phosphorylation of the adaptor protein SHC, leading to GRB2 recruitment and RAS activation. Activated RAS recruits RAF to the cytoplasmic membrane, where it can be activated by protein kinases such as SRC, thereby leading to mitogen-activated protein kinase kinase (MEK) and ERK activation. Once activated by FAK or SHC, RAS can activate PI3K and RAF. Activated SRC can also phosphorylate CRK-associated substrate (CAS), leading to RAC activation. Activated RAC, in conjunction with activated CDC42 and with activated ERK, can then regulate numerous biochemical pathways that are necessary for the migratory phenotype (Hood and Cheresh, 2002).

In addition to integrin receptor switching, a switch in the expression of cadherins (another class of molecules implicated in cell adhesion) also plays a significant role in the invasive properties of both normal trophoblasts and malignant cells. In the placenta, the adhesion molecule E-cadherin mediates a strong intracellular interaction between cytotrophoblasts, as it does in all other normal epithelia (Birchmeier, 1995; Zhou *et al.*, 1997a). When cytotrophoblasts differentiate in cell columns and move into the placental bed, E-cadherin expression is progressively lost. Similarly, E-cadherin function is apparently lost in a majority of epithelial cancers (Irish *et al.*, 2006). Because E-cadherin serves as a widely acting suppressor of invasion and metastasis by epithelial cancers, its functional elimination represents a key step in the acquisition of this capacity. Thus, cadherin modulation, like integrin modulation, contributes to the acquisition of an invasive phenotype by differentiating cytotrophoblasts (Damsky *et al.*,

1994). Cadherins are generally regulated at both the mRNA and the protein level by means of changes in subcellular distribution, translational or transcriptional events and degradation. Various signal transduction pathways impact the regulation of E-cadherin levels and subcellular distribution. Very recently, AKT, a downstream effector of PI3K, was shown to regulate levels of E-cadherin mRNA and protein: at the molecular level, AKT represses transcription of the E-cadherin gene. Moreover, cells producing a constitutively active form of AKT produce a transcription factor, Snail, which is known to repress the expression of the E-cadherin gene (Grille *et al.*, 2003; Larue and Bellacosa, 2005).

A switch in the expression of different immunoglobulin superfamily adhesion receptors also accompanies the acquisition of invasive capacities by both normal trophoblastic and neoplastic cells. Cytotrophoblasts differentiating along the invasive pathway up-regulate the expression of immunoglobulin superfamily adhesion receptors characteristic of endothelial cells. Vascular adhesion molecule-1 (VCAM-1), which interacts with integrins $\alpha 4\beta 1$ and $\alpha 4\beta 7$, is not detected on vCTBs, but it is detected on evCTBs within the uterine wall. Its expression on endovascular cytotrophoblasts is particularly strong. vCTBs do not express another member of the immunoglobulin superfamily adhesion receptors, platelet endothelial adhesion molecule-1 (PECAM-1); however, this adhesion molecule, which can interact with itself or with $\alpha v\beta 3$ (Piali *et al.*, 1995), is expressed on cytotrophoblasts within cell columns. Cells involved in both interstitial and endovascular invasion display particularly potent expression (Zhou *et al.*, 1997a). The highly invasive behaviour of these evCTBs may account for the virtually unique ability to enter blood vessels, displace resident endothelial cells and colonize and remodel the arterial wall.

Changes in the expression of CAMs in the immunoglobulin superfamily also appear to play a critical role in the processes of invasion and metastasis (Johnson, 1991). The clearest case involves N-CAM, which undergoes a switch in expression from a highly adhesive isoform to poorly adhesive (or even repulsive) forms in Wilms' tumour, neuroblastoma and small cell lung cancer (Johnson, 1991; Kaiser *et al.*, 1996) and a reduction in the overall expression level in invasive pancreatic and colorectal cancers (Fogar *et al.*, 1997).

Proteinase production

Decidual invasion by cytotrophoblasts results from classical steps in cellular invasion, including attachment to the basement membrane followed by detachment and proteolysis of the basement membrane before its penetration. Thus, invasion is not due to passive growth pressure but rather due to active secretion of enzymes capable of degrading the ECM in which the cells are embedded, and cytotrophoblast cells are no exception (Fisher *et al.*, 1985; Bischof and Campana, 2000; Mock *et al.*, 2000). Interestingly, similar enzymatic mechanisms are shared by trophoblastic and malignant cells in the invasive process, and the degradation of basement membranes during metastasis is in part regulated by proteolysis, often by the same proteases implicated in implantation (Testa and Quigley, 1990; Leone *et al.*, 1991; Strickland and Richards, 1992). However, these enzymatic mechanisms are employed in a highly concerted manner only in the trophoblast: in contrast to

that of tumours, the invasive behaviour of cytotrophoblasts is acquired only transiently.

Early during implantation, trophoblastic cells from the outer layer of the blastocyst invade the endometrium by secretion of matrix-degrading proteases (Iruela-Arispe, 1997). ECM-degrading proteinases, such as MMP-9 and uPA, regulate placental development (Librach *et al.*, 1991; Zhang *et al.*, 1996). Later, after implantation, evCTBs leaving the proliferative cell cluster acquire an invasive phenotype that is characterized not only by a switch in their adhesion molecule expression (Damsky *et al.*, 1992; Zhou *et al.*, 1997b; Shih Ie *et al.*, 2002) but also by the production of a set of proteases: metalloproteinases (Vettraino *et al.*, 1996; Hurskainen *et al.*, 1998; Mock *et al.*, 2000), serine proteases (Liu *et al.*, 2003) and cathepsin (Divya *et al.*, 2002), which degrade the ECM (Lacroix *et al.*, 2005). Indeed, invasive evCTB cells display elevated expression of matrix-degrading proteinases, as do cancer cells (Mignatti *et al.*, 1986; Stetler-Stevenson *et al.*, 1993; Huppertz *et al.*, 1998). For example, they increase their production and activation of MMP-9 (gelatinase B, MMP-9), which contributes to the invasiveness of cytotrophoblasts *in vitro* (Librach *et al.*, 1991; Bass *et al.*, 1997; Schatz *et al.*, 1999). Cytotrophoblast production and activation of MMP-9 peak during the first trimester, coinciding with maximal invasive behaviour *in vivo* (Librach *et al.*, 1991; Bass *et al.*, 1994; Cross *et al.*, 1994; Shimonovitz *et al.*, 1994). Moreover, MMP-2 (gelatinase A, MMP-2) is also expressed in evCTBs, but accumulating evidence suggests that MMP-9 may play a more important role than MMP-2 in trophoblast invasion during pregnancy and that MMP-9 expression/activation is a prerequisite to evCTB invasion (Cohen *et al.*, 2006b). Thus, mechanisms regulating the expression of MMP-9 are important for evCTB invasion. MMP-9 secretion in invasive cytotrophoblasts is stimulated by various factors including TNF- α (Meisser *et al.*, 1999) and EGF (Qiu *et al.*, 2004a,b), whereas TGF- β inhibits trophoblastic MMP-9 secretion (Meisser *et al.*, 1999). TIMPs are also important regulators of MMP activity (Denhardt *et al.*, 1993). Although several members of the TIMP family have been identified, proteolysis by MMP-9 is mostly regulated by the action of endogenous TIMP-1 (Itoh and Nagase, 1995). Thus, it is noteworthy that EGF induces the secretion of not only MMP-9 but also TIMP-1, identifying this growth factor produced by trophoblastic cells as one of the key regulators of trophoblast invasion. Recently, it was convincingly demonstrated *in vitro* that EGF induces MMP-9 and TIMP-1 secretion through simultaneous activation of both the PI3K and MAPK signalling pathways in evCTBs, resulting in the activation of several transcription factors (Qiu *et al.*, 2004a,b; Pollheimer and Knofler, 2005), as is the case in cancer cells (Vivanco and Sawyers, 2002; Cully *et al.*, 2006). For instance, EGF activates the PI3K and MAPK/ERK pathways, which modulate the activation of NF κ B and AP-1, respectively, in human head and neck squamous cell carcinoma lines (Bancroft *et al.*, 2002), whereas transcription factors Ets-1 and Ets-2 are activated in response to EGF in human breast tumour cells (Watabe *et al.*, 1998).

Amongst serine proteases, the serine protease uPA promotes matrix degradation by extravillous trophoblasts, and it was shown that uPA stimulates human extravillous trophoblast migration by using phospholipase C, PI3K and MAPK (Liu *et al.*, 2003). Other enzymes such as heparanase are secreted by trophoblasts and

cancer cells and have been implicated in the invasive behaviour of these cells (Vlodavsky *et al.*, 1999; Dempsey *et al.*, 2000). The overexpression of heparanase cDNA in weakly metastatic tumour cells confers high metastatic potential in experimental animals (Vlodavsky *et al.*, 1999), suggesting a critical role for heparanase during cell invasion associated with tumour metastasis and angiogenesis (Nakajima *et al.*, 1988; Vlodavsky *et al.*, 1999; Elkin *et al.*, 2001; Parish *et al.*, 2001).

Finally, the activation of extracellular proteases and the altered binding specificity of cadherins, CAMs and integrins are clearly

central to the acquisition of invasiveness by trophoblasts and to the acquisition of metastatic ability by malignant cells. However, the regulatory circuits and molecular mechanisms that govern these shifts remain elusive and, at present, seem to differ from one tissue environment to another.

Immune escape

To invade neighbouring tissues, normal trophoblastic and malignant non-trophoblastic cells must escape effectors of the immune




Figure 3. Schematic map of major signalling pathways (molecular circuitries) that may be shared by both trophoblastic and malignant cells so as to acquire six traits important for malignant growth: tissue invasion and metastasis (green), insensitivity to growth-inhibitory (antigrowth) signals (dark blue), sustained angiogenesis (red), self-sufficiency in growth signals (light blue), limitless replicative potential (brown) and evasion of programmed cell death (apoptosis) (orange) (Hanahan and Weinberg, 2000; Hahn and Weinberg, 2002). This figure simplifies complex interacting regulatory networks. Casp, caspases; CDK, cyclin-dependent kinase; CYC, cyclin; EGF, epidermal growth factor; erbB2, HER2/neu receptor tyrosine kinase; FAK, focal adhesion kinase; GRB2, growth-factor-receptor-bound protein 2; HIF, hypoxia-inducible factor; IGF-1 and IGF-2, insulin-like growth factors 1 and 2; IRS1, insulin-receptor substrate 1; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; MEKK, MAPK kinase kinase; MET, hepatocyte growth factor/scatter factor (HGF/SF) receptor; MMP, matrix metalloproteinase; MT-MMP, membrane-type matrix metalloproteinase; PDGF, platelet-derived growth factor PI3K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol(3,4,5)triphosphate; PTEN, phosphatase and tensin homologue; SHC, SRC-homology-2-domain transforming protein; SRC, Src family kinase; STATs, signal transducers and activators of transcription; TGF- α , transforming growth factor- α ; TGF- β , transforming growth factor- β ; TIMP, tissue inhibitor of metalloproteinase; TNF- α , tumour necrosis factor- α ; TOR, target of rapamycin; uPA, urokinase plasminogen activator.

system. Remarkably, maternal immune surveillance of foreign cell-surface antigens fails to reject the embryonic conceptus despite the expression of paternal antigens on trophoblasts. The placenta separates fetal and maternal blood and lymphatic systems, and it is the fetal trophoblast that plays the most important role in the evasion of recognition by the maternal immune system (Weetman, 1999). Trophoblast cells fail to express major histocompatibility complex (MHC) class I or class II molecules. Similarly, MHC class I down-regulation is an important mechanism in tumour escape from T-cell-mediated immune responses: approximately 40–90% of human tumours have been reported to be MHC class I deficient (Bubenik, 2003). Moreover, evCTB cells strongly express the non-classic MHC gene encoding HLA-G, which may down-regulate natural killer (NK) cell function. Using other mechanisms, tumours induce, in NK cells, the same inactivating reactions that the fetal trophoblast engenders *in utero* (Sinkovics and Horvath, 2005). In addition, the trophoblast expresses the Fas ligand (FasL/CD95L), thereby conferring an immune privilege (a property of some sites in the body whereby immune responses are limited or prevented): maternal immune cells expressing Fas will undergo apoptosis at the placental/decidual interface. Tumour cells frequently exhibit de-novo expression of Fas ligand. Coupled with resistance to Fas-mediated apoptosis, FasL expression enables many cancers to deliver a pre-emptive strike against or to ‘counterattack’ the immune system (Houston and O’Connell, 2004). However, a role for FasL in immune privilege has been challenged (Green and Ferguson, 2001).

Corresponding molecular circuitries of proliferation, migration and invasion

Cells respond to extracellular stimuli through a series of signalling cascades. From receptor activation to a biological effect, each signal follows a pathway recruiting effectors and adapters, varieties of proteins that interact with each other and generating a cascade of sequential steps (Knofler *et al.*, 2005). Some pathways are linear, whereas others are branched, and some are linked to others to induce specific or redundant events. However, most of the time, signalling molecules are common to several pathways, forming a complex intracellular network (Knofler *et al.*, 2005). Under intensive study for two decades, the wiring diagram of the signalling circuitry of the mammalian cell, while incomplete, is coming into focus, and it is now possible to lay out a circuitry that will likely mimic electronic integrated circuits (Hanahan and Weinberg, 2000). Moreover, it was suggested that most and perhaps all types of human tumours share six essential alterations in cell physiology that collectively dictate malignant growth: self-sufficiency in GS, insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), limitless replicative potential, sustained angiogenesis and tissue invasion and metastasis. An overview of signalling circuitries used by trophoblast cells, although simplistic, places emphasis on the many circuitries shared with those employed by cancer cells (Figure 3). As virtually all mammalian cells carry similar molecular machinery regulating their proliferation, differentiation and death (Hanahan and Weinberg, 2000) and as most regulatory and effector components are present in a redundant form, it is not totally surprising that normal trophoblasts and malignant cells, which may have to accomplish comparable tasks to proliferate and migrate so as to

ultimately invade neighbouring tissue, use, in part, similar regulatory and effector components, similar circuitries and similar mechanisms, even though the finale of these processes is strikingly different. Moreover, it should be recalled that the main difference between normal trophoblast development and malignant transformation is that cellular and molecular events follow highly regulated spatial and temporal plans during trophoblast development, whereas during malignant transformation, the order of events may be stochastic and time independent or particular events may be bypassed.

Conclusion

The ability of trophoblast cells to proliferate and then to migrate and invade the uterine wall, as well as the many common characteristics shared by normal trophoblast cells and malignant cells, makes them ideal for monitoring molecular changes taking place during the acquisition of a migrating/invasive phenotype. Moreover, normal trophoblast can be transformed into hydatidiform mole, a highly proliferative benign trophoblastic disease (Berkowitz and Goldstein, 1996), and into choriocarcinoma, one of the most metastatic tumours known (Strickland and Richards, 1992). Chorionic tumours are characterized by progressive loss of control of the proliferation, migration and invasion normally achieved by trophoblast cells. Taken together, trophoblast cells from normal placenta, hydatidiform mole and choriocarcinoma constitute a unique and fascinating model for studying mechanisms involved in these processes. Careful analysis and comparison of different trophoblast model systems will help gain valuable insight not only into the exciting area of trophoblast research but also into the vast field of cancer research.

Indeed, we are likely to derive much more from the trophoblast than simply the elucidation of the molecular mechanisms controlling migration and invasion processes. The parallel between these cells, which form the basis of life, and malignant cells, which bear the possibility of death, offers us an occasion for reflection, not without irony, on the value of human existence and its inherent fragility.

Acknowledgements

We thank Jerri Bram and Agnes Bellet for their valuable help. Grant support: Patrick Roy Translational Medicine grant.

References

- Acs G, Zhang PJ, Rebbeck TR, Acs P and Verma A (2002) Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. *Cancer* 95,969–981.
- Ahmed MS, Cemerikic B and Agbas A (1992) Properties and functions of human placental opioid system. *Life Sci* 50,83–97.
- Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI and Rollason T (1995) Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. *Growth Factors* 12,235–243.
- Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M and Buck CA (1990) Integrin distribution in malignant melanoma, association of the beta 3 subunit with tumour progression. *Cancer Res* 50,6757–6764.
- Alitalo K, Schwab M, Lin CC, Varmus HE and Bishop JM (1983) Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. *Proc Natl Acad Sci USA* 80,1707–1711.

- Aoyagi K, Shima I, Wang M, Hu Y, Garcia FU and Stearns ME (1998) Specific transcription factors prognostic for prostate cancer progression. *Clin Cancer Res* 4,2153–2160.
- Aplin AE, Howe A, Alahari SK and Juliano RL (1998) Signal transduction and signal modulation by cell adhesion receptors, the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. *Pharmacol Rev* 50,197–263.
- Arcuri F, Cintonino M, Florio P, Floccari F, Pergola L, Romagnoli R, Petraglia F, Tosi P and Teresa Del Vecchio M (2002) Expression of uroctin mRNA and peptide in the human prostate and in prostatic adenocarcinoma. *Prostate* 52,167–172.
- Athanassiades A and Lala PK (1998) Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. *Placenta* 19,465–473.
- Athanassiades A, Hamilton GS and Lala PK (1998) Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillous trophoblast. *Biol Reprod* 59,643–654.
- Bajoria R and Babawale M (1998) Ontogeny of endogenous secretion of immunoreactive-thyrotropin releasing hormone by the human placenta. *J Clin Endocrinol Metab* 83,4148–4155.
- Bamberger AM, Sudahl S, Wagener C and Loning T (2001) Expression pattern of the adhesion molecule CEACAM1 (C-CAM, CD66a, BGP) in gestational trophoblastic lesions. *Int J Gynecol Pathol* 20,160–165.
- Bamberger AM, Bamberger CM, Aupers S, Milde-Langosch K, Loning T and Makrigiannakis A (2004) Expression pattern of the activating protein-1 family of transcription factors in the human placenta. *Mol Hum Reprod* 10,223–228.
- Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C and Van Waes C (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. *Int J Cancer* 99,538–548.
- Bass KE, Morrish D, Roth I, Bhardwaj D, Taylor R, Zhou Y and Fisher SJ (1994) Human cytotrophoblast invasion is up-regulated by epidermal growth factor, evidence that paracrine factors modify this process. *Dev Biol* 164,550–561.
- Bass KE, Li H, Hawkes SP, Howard E, Bullen E, Vu TK, McMaster M, Janatpour M and Fisher SJ (1997) Tissue inhibitor of metalloproteinase-3 expression is upregulated during human cytotrophoblast invasion in vitro. *Dev Genet* 21,61–67.
- Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM and Birchmeier W (1993) Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. *J Cell Biol* 120,757–766.
- Bellet D, Lavaissiere L, Mock P, Laurent A, Sabourin JC, Bedossa P, Le Bouteiller P, Frydman R, Troalen F and Bidart JM (1997a) Identification of pro-EPIL and EPIL peptides translated from insulin-like 4 (INSL4) mRNA in human placenta. *J Clin Endocrinol Metab* 82,3169–3172.
- Bellet D, Lazar V, Bieche I, Paradis V, Giovangrandi Y, Paterlini P, Lidereau R, Bedossa P, Bidart JM and Vidaud M (1997b) Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. *Cancer Res* 57,516–523.
- Bellone S, Watts K, Cane S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S and Santin AD (2005) High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. *Gynecol Oncol* 98,92–98.
- Berkowitz RS and Goldstein DP (1996) Chorionic tumours. *N Engl J Med* 335,1740–1748.
- Bilban M, Ghaffari-Tabrizi N, Hintermann E, Bauer S, Molzer S, Zoratti C, Malli R, Sharabi A, Hiden U, Graier W et al. (2004) Kisspeptin-10, a KiSS-1/metastatin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. *J Cell Sci* 117,1319–1328.
- Birchmeier W (1995) E-cadherin as a tumour (invasion) suppressor gene. *Bioessays* 17,97–99.
- Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF (2003) Met, metastasis, motility and more. *Nat Rev Mol Cell Biol* 4,915–925.
- Bischof P (2001) Endocrine, paracrine and autocrine regulation of trophoblastic metalloproteinases. *Early Pregnancy* 5,30–31.
- Bischof P and Campana A (2000) A putative role for oncogenes in trophoblast invasion? *Hum Reprod* 15(Suppl 6),51–58.
- Bischof P, Meisser A and Campana A (2000) Paracrine and autocrine regulators of trophoblast invasion—a review. *Placenta* 21(Suppl A),S55–S60.
- Bishayee S, Matesic D and Das M (1984) Identification of a 34,000-dalton mitogenic protein associated with plasma membranes from human A431 epidermoid carcinoma cells. *Proc Natl Acad Sci USA* 81,3399–3403.
- Bishop JM (1987) The molecular genetics of cancer. *Science* 235,305–311.
- Bjorn SF, Hastrup N, Larsen JF, Lund LR and Pyke C (2000) Messenger RNA for membrane-type 2 matrix metalloproteinase, MT2-MMP, is expressed in human placenta of first trimester. *Placenta* 21,170–176.
- Boire A, Covic L, Agarwal A, Jacques S, Sherifi S and Kuliopulos A (2005) PARI is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. *Cell* 120,303–313.
- Bonduelle ML, Dodd R, Liebaers I, Van Steirteghem A, Williamson R and Akhurst R (1988) Chorionic gonadotrophin-beta mRNA, a trophoblast marker, is expressed in human 8-cell embryos derived from tripronucleate zygotes. *Hum Reprod* 3,909–914.
- Bonnerette J, Peyrat JP, Beuscart R and Demaille A (1990) Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer. *J Steroid Biochem Mol Biol* 37,977–981.
- Bostwick DG, Null WE, Holmes D, Weber E, Barchas JD and Bensch KG (1987) Expression of opioid peptides in tumours. *N Engl J Med* 317,1439–1443.
- Boyd JH (1980) *The Human Placenta*. Macmillan, London.
- Brandt B, Roetger A, Bidart JM, Packeisen J, Schier K, Mikesch JH, Kemming D, Boecker W, Yu D and Buerger H (2002) Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential. *Cancer Res* 62,1020–1024.
- Briese J, Oberndorfer M, Patschenik C, Schulte HM, Makrigiannakis A, Loning T and Bamberger AM (2005a) Osteopontin is colocalized with the adhesion molecule CEACAM1 in the extravillous trophoblast of the human placenta and enhances invasion of CEACAM1-expressing placental cells. *J Clin Endocrinol Metab* 90,5407–5413.
- Briese J, Oberndorfer M, Schulte HM, Loning T and Bamberger AM (2005b) Osteopontin expression in gestational trophoblastic diseases, correlation with expression of the adhesion molecule, CEACAM1. *Int J Gynecol Pathol* 24,271–276.
- Bryant-Greenwood GD, Rees MC and Turnbull AC (1987) Immunohistochemical localization of relaxin, prolactin and prostaglandin synthase in human amnion, chorion and decidua. *J Endocrinol* 114,491–496.
- Bubenik J (2003) Tumour MHC class I downregulation and immunotherapy (Review). *Oncol Rep* 10,2005–2008.
- Butt AJ, Firth SM and Baxter RC (1999) The IGF axis and programmed cell death. *Immunol Cell Biol* 77,256–262.
- Calaf GM and Hei TK (2004) Ionizing radiation induces alterations in cellular proliferation and c-myc, c-jun and c-fos protein expression in breast epithelial cells. *Int J Oncol* 25,1859–1866.
- Campbell S, Swann HR, Seif MW, Kimber SJ and Aplin JD (1995) Cell adhesion molecules on the oocyte and preimplantation human embryo. *Hum Reprod* 10,1571–1578.
- Caniggia I, Lye SJ and Cross JC (1997) Activin is a local regulator of human cytotrophoblast cell differentiation. *Endocrinology* 138,3976–3986.
- Cartwright JE, Tse WK and Whitley GS (2002) Hepatocyte growth factor induced human trophoblast motility involves phosphatidylinositol-3-kinase, mitogen-activated protein kinase, and inducible nitric oxide synthase. *Exp Cell Res* 279,219–226.
- Carvalho I, Milanezi F, Martins A, Reis RM and Schmitt F (2005) Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. *Breast Cancer Res* 7,788–795.
- Castellucci M, De Matteis R, Meisser A, Canello R, Monsurro V, Islami D, Sarzani R, Marziani D, Cinti S and Bischof P (2000) Leptin modulates extracellular matrix molecules and metalloproteinases, possible implications for trophoblast invasion. *Mol Hum Reprod* 6,951–958.
- Chakraborty C, Gleason LM, McKinnon T and Lala PK (2002) Regulation of human trophoblast migration and invasiveness. *Can J Physiol Pharmacol* 80,116–124.
- Champelovier P, Boucard N, Levacher G, Simon A, Seigneurin D and Praloran V (2002) Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma, diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. *Urol Res* 30,301–309.
- Chen ME, Lin SH, Chung LW and Sikes RA (1998) Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. *J Biol Chem* 273,17618–17625.
- Chibbar R, Miller FD and Mitchell BF (1993) Synthesis of oxytocin in amnion, chorion, and decidua may influence the timing of human parturition. *J Clin Invest* 91,185–192.

- Chou CS, Beristain AG, MacCalman CD and Leung PC (2004) Cellular localization of gonadotropin-releasing hormone (GnRH) I and GnRH II in first-trimester human placenta and decidua. *J Clin Endocrinol Metab* 89,1459–1466.
- Ciarmela P, Florio P, Sigurdardottir M, Toti P, Maguer-Satta V, Rimokh R, Altomare A, Tosi P and Petraglia F (2004) Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinoma. *Eur J Endocrinol* 151,251–257.
- Clark DE, Smith SK, Sharkey AM and Charnock-Jones DS (1996) Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. *Hum Reprod* 11,1090–1098.
- Clifton VL, Gu Q, Murphy VE, Schwartz J, Madsen G and Smith R (2000) Localization and characterization of urocortin during human pregnancy. *Placenta* 21,782–788.
- Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I and Abramovitch R (2006a) Heparanase promotes growth, angiogenesis and survival of primary breast tumours. *Int J Cancer* 118,1609–1617.
- Cohen M, Meisser A and Bischof P (2006b) Metalloproteinases and human placental invasiveness. *Placenta* 27,783–793.
- Conrad KP, Benyo DF, Westerhausen-Larsen A and Miles TM (1996) Expression of erythropoietin by the human placenta. *FASEB J* 10,760–768.
- Crisi GM, Marconi SA, Makari-Judson G and Goulart RA (2005) Expression of c-kit in adenoid cystic carcinoma of the breast. *Am J Clin Pathol* 124,733–739.
- Cross JC, Werb Z and Fisher SJ (1994) Implantation and the placenta, key pieces of the development puzzle. *Science* 266,1508–1518.
- Cully M, You H, Levine AJ and Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. *Nat Rev Cancer* 6,184–192.
- Dagnon K, Pacary E, Commo F, Antoine M, Bernaudin M, Bernaudin JF and Callard P (2005) Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. *Clin Cancer Res* 11,993–999.
- Damsky CH and Fisher SJ (1998) Trophoblast pseudo-vasculogenesis, faking it with endothelial adhesion receptors. *Curr Opin Cell Biol* 10,660–666.
- Damsky CH, Fitzgerald ML and Fisher SJ (1992) Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, *in vivo*. *J Clin Invest* 89,210–222.
- Damsky CH, Librach C, Lim KH, Fitzgerald ML, McMaster MT, Janatpour M, Zhou Y, Logan SK and Fisher SJ (1994) Integrin switching regulates normal trophoblast invasion. *Development* 120,3657–3666.
- Dang CV, O'Donnell KA and Juopperi T (2005) The great MYC escape in tumorigenesis. *Cancer Cell* 8,177–178.
- Das R, Mahabeshwar GH and Kundu GC (2004) Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. *J Biol Chem* 279,11051–11064.
- De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P *et al.* (1999) Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. *Cancer Res* 59,3157–3165.
- Dempsey LA, Plummer TB, Coombes SL and Platt JL (2000) Heparanase expression in invasive trophoblasts and acute vascular damage. *Glycobiology* 10,467–475.
- Deng H, Guo RF, Li WM, Zhao M and Lu YY (2005) Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. *Biochem Biophys Res Commun* 326,274–281.
- Denhardt DT, Feng B, Edwards DR, Cocuzzi ET and Malyankar UM (1993) Tissue inhibitor of metalloproteinases (TIMP, aka EPA), structure, control of expression and biological functions. *Pharmacol Ther* 59,329–341.
- Divya Chhikara P, Mahajan VS, Datta Gupta S and Chauhan SS (2002) Differential activity of cathepsin L in human placenta at two different stages of gestation. *Placenta* 23,59–64.
- Donea L, Bulfamante G, Grimoldi MG, Volpi L and Larizza L (1997) Localization of fos, jun, kit and SCF mRNA in human placenta throughout gestation using *in situ* RT-PCR. *Early Pregnancy* 3,265–271.
- Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH and Meng XY (2005) Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. *World J Gastroenterol* 11,4655–4660.
- Downward J (2003) Targeting RAS signalling pathways in cancer therapy. *Nat Rev Cancer* 3,11–22.
- Duan C, Bauchat JR and Hsieh T (2000) Phosphatidylinositol 3-kinase is required for insulin-like growth factor-I-induced vascular smooth muscle cell proliferation and migration. *Circ Res* 86,15–23.
- Dungy LJ, Siddiqi TA and Khan S (1991) Transforming growth factor-beta 1 expression during placental development. *Am J Obstet Gynecol* 165,853–857.
- Egan DA, Grzegorzczak V, Tricarico KA, Rueter A, Holleman WH and Marcotte PA (1988) Human placental chorionic renin, production, purification and characterization. *Biochim Biophys Acta* 965,68–75.
- Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Pappo O, Pecker I and Vlodavsky I (2001) Heparanase as mediator of angiogenesis, mode of action. *FASEB J* 15,1661–1663.
- Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, Johnson MM, Gunn DC, Yekell S and Grimm EA (2004) Expression of thyrotropin-releasing hormone by human melanoma and nevi. *Clin Cancer Res* 10,5531–5536.
- Estreicher A, Muhlhauser J, Carpentier JL, Orci L and Vassalli JD (1990) The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. *J Cell Biol* 111,783–792.
- Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I and Bar-Shavit R (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. *Nat Med* 4,909–914.
- Fairchild Benyo D and Conrad KP (1999) Expression of the erythropoietin receptor by trophoblast cells in the human placenta. *Biol Reprod* 60,861–870.
- Felding-Habermann B, Mueller BM, Romerdahl CA and Cheresch DA (1992) Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. *J Clin Invest* 89,2018–2022.
- Fingar DC and Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. *Oncogene* 23,3151–3171.
- Fisher SJ, Leitch MS, Kantor MS, Basbaum CB and Kramer RH (1985) Degradation of extracellular matrix by the trophoblastic cells of first-trimester human placentas. *J Cell Biochem* 27,31–41.
- Floridon C, Nielsen O, Holund B, Sunde L, Westergaard JG, Thomsen SG and Teisner B (1999) Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies. *Placenta* 20,711–721.
- Florio P, Franchini A, Reis FM, Pezzani I, Ottaviani E and Petraglia F (2000) Human placenta, chorion, amnion and decidua express different variants of corticotropin-releasing factor receptor messenger RNA. *Placenta* 21,32–37.
- Florio P, Rossi M, Sigurdardottir M, Ciarmela P, Luisi S, Vignano P, Grasso D, Fiore G, Cobellis L, Di Blasio AM *et al.* (2003) Paracrine regulation of endometrial function, interaction between progesterone and corticotropin-releasing factor (CRF) and activin A. *Steroids* 68,801–807.
- Fogar P, Basso D, Pasquali C, De Paoli M, Sperti C, Roveroni G, Pedrazzoli S and Plebani M (1997) Neural cell adhesion molecule (N-CAM) in gastrointestinal neoplasias. *Anticancer Res* 17,1227–1230.
- Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I and Pappo O (2000) Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. *Am J Pathol* 157,1167–1175.
- Fruutuoso C, Silva MR, Amaral N, Martins I, De Oliveira C and De Oliveira HM (2001) Prognosis value of p53, C-erbB-2 and Ki67 proteins in ovarian carcinoma. *Acta Med Port* 14,277–283.
- Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I and Berkowitz RS (1998) c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. *J Reprod Med* 43,101–110.
- Gabarra-Niecko V, Schaller MD and Dunty JM (2003) FAK regulates biological processes important for the pathogenesis of cancer. *Cancer Metastasis Rev* 22,359–374.
- Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R and Royuela M (2005) IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and *in situ* human breast carcinoma. *Histopathology* 47,82–89.
- Geisler JP, Geisler HE, Manahan KJ, Miller GA, Wiemann MC, Zhou Z and Crabtree W (2004) Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival. *Int J Gynecol Cancer* 14,133–137.
- Genbacev O, Zhou Y, Ludlow JW and Fisher SJ (1997) Regulation of human placental development by oxygen tension. *Science* 277,1669–1672.
- Gerber HP, Condorelli F, Park J and Ferrara N (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. *J Biol Chem* 272,23659–23667.

- Giancotti FG and Ruoslahti E (1990) Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. *Cell* 60,849–859.
- Giani C, Campani D, Rasmussen A, Fierabracci P, Miccoli P, Bevilacqua G, Pinchera A and Cullen KJ (2002) Insulin-like growth factor II (IGF-II) immunohistochemistry in breast cancer, relationship with the most important morphological and biochemical prognostic parameters. *Int J Biol Markers* 17,90–95.
- Goode BL, Drubin DG and Barnes G (2000) Functional cooperation between the microtubule and actin cytoskeletons. *Curr Opin Cell Biol* 12,63–71.
- Goustin AS, Betsholtz C, Pfeifer-Ohlsson S, Persson H, Rydner J, Bywater M, Holmgren G, Heldin CH, Westermark B and Ohlsson R (1985) Coexpression of the sis and myc proto-oncogenes in developing human placenta suggests autocrine control of trophoblast growth. *Cell* 41,301–312.
- Graves DT, Owen AJ, Barth RK, Tempst P, Winoto A, Fors L, Hood LE and Antoniades HN (1984) Detection of c-sis transcripts and synthesis of PDGF-like proteins by human osteosarcoma cells. *Science* 226,972–974.
- Green DR and Ferguson TA (2001) The role of Fas ligand in immune privilege. *Nat Rev Mol Cell Biol* 2,917–924.
- Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tschlis PN and Larue L (2003) The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. *Cancer Res* 63,2172–2178.
- Grouzmann E, Deruaz JP, Gomez F and Waeber G (1998) Immunolocalization of neuropeptide Y in human pituitary tumours. *Regul Pept* 75–76,89–92.
- Grundker C and Emons G (2003) Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. *Reprod Biol Endocrinol* 1,65.
- Grundker C, Gunthert AR, Westphalen S and Emons G (2002) Biology of the gonadotropin-releasing hormone system in gynecological cancers. *Eur J Endocrinol* 146,1–14.
- Gschwind A, Fischer OM and Ullrich A (2004) The discovery of receptor tyrosine kinases, targets for cancer therapy. *Nat Rev Cancer* 4,361–370.
- Guo W and Giancotti FG (2004) Integrin signalling during tumour progression. *Nat Rev Mol Cell Biol* 5,816–826.
- Gupta PB, Kupervasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP and Weinberg RA (2005) The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. *Nat Genet* 37,1047–1054.
- Gurski MR, Gonzalez E and Brown EG (1999) Immunohistochemical localization of platelet-derived growth factor in placenta and its possible role in pre-eclampsia. *J Invest Med* 47,128–133.
- Hahn WC and Weinberg RA (2002) Modelling the molecular circuitry of cancer. *Nat Rev Cancer* 2,331–341.
- Haimov-Kochman R, Friedmann Y, Prus D, Goldman-Wohl DS, Greenfield C, Anteby EY, Aviv A, Vladavsky I and Yagel S (2002) Localization of heparanase in normal and pathological human placenta. *Mol Hum Reprod* 8,566–573.
- Hall A (1998) Rho GTPases and the actin cytoskeleton. *Science* 279,509–514.
- Hamilton GS, Lysiak JJ, Watson AJ and Lala PK (1998) Effects of colony stimulating factor-1 on human extravillous trophoblast growth and invasion. *J Endocrinol* 159,69–77.
- Han SU, Lee HY, Lee JH, Kim WH, Nam H, Kim H, Cho YK, Kim MW and Lee KU (2005) Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. *Ann Surg* 242,676–683.
- Hanahan D and Weinberg RA (2000) The hallmarks of cancer. *Cell* 100,57–70.
- Hantschel O and Superti-Furga G (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. *Nat Rev Mol Cell Biol* 5,33–44.
- Haynes MK, Jackson LG, Tuan RS, Shepley KJ and Smith JB (1993) Cytokine production in first trimester chorionic villi, detection of mRNAs and protein products in situ. *Cell Immunol* 151,300–308.
- Henic E, Sixt M, Hansson S, Hoyer-Hansen G and Casslen B (2006) EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. *Gynecol Oncol* 101,28–39.
- Hesketh R (1995) *The Oncogene Fact Book*. Academic Press, New York.
- Hofmann GE, Drews MR, Scott RT Jr, Navot D, Heller D and Deligdisch L (1992) Epidermal growth factor and its receptor in human implantation trophoblast, immunohistochemical evidence for autocrine/paracrine function. *J Clin Endocrinol Metab* 74,981–988.
- Hood JD and Cheresch DA (2002) Role of integrins in cell invasion and migration. *Nat Rev Cancer* 2,91–100.
- Hood BL, Darfler MM, Guilel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD and Krizman DB (2005) Proteomic analysis of formalin fixed prostate cancer tissue. *Mol Cell Proteomics* 1535–9476.
- Horowitz GM, Scott RT Jr, Drews MR, Navot D and Hofmann GE (1993) Immunohistochemical localization of transforming growth factor-alpha in human endometrium, decidua, and trophoblast. *J Clin Endocrinol Metab* 76,786–792.
- Houston A and O'Connell J (2004) The Fas signalling pathway and its role in the pathogenesis of cancer. *Curr Opin Pharmacol* 4,321–326.
- Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ and Tang BJ (2004) [Expression of matrix metalloproteinases-9,2,7, and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumours and their clinical significance]. *Ai Zhong* 23,1194–1198.
- Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM et al. (2003) Gene expression predictors of breast cancer outcomes. *Lancet* 361,1590–1596.
- Huppertz B, Kertschanska S, Demir AY, Frank HG and Kaufmann P (1998) Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. *Cell Tissue Res* 291,133–148.
- Hurskainen T, Seiki M, Apte SS, Syrjakallio-Ylitalo M, Sorsa T, Oikarinen A and Autio-Harmanen H (1998) Production of membrane-type matrix metalloproteinase-1 (MT-MMP-1) in early human placenta. A possible role in placental implantation? *J Histochem Cytochem* 46,221–229.
- Hynes NE and Lane HA (2005) ERBB receptors and cancer, the complexity of targeted inhibitors. *Nat Rev Cancer* 5,341–354.
- Ide H, Seligson DB, Memarzadeh S, Xin L, Horvath S, Dubey P, Flick MB, Kacinski BM, Palotie A and Witte ON (2002) Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. *Proc Natl Acad Sci USA* 99,14404–14409.
- Ilic D, Genbacev O, Jin F, Caceres E, Almeida EA, Bellingard-Dubouchaud V, Schaefer EM, Damsky CH and Fisher SJ (2001) Plasma membrane-associated pY397FAK is a marker of cytotrophoblast invasion in vivo and in vitro. *Am J Pathol* 159,93–108.
- Ilvesmaki V, Kahri AI, Miettinen PJ and Voutilainen R (1993) Insulin-like growth factors (IGFs) and their receptors in adrenal tumours, high IGF-II expression in functional adrenocortical carcinomas. *J Clin Endocrinol Metab* 77,852–858.
- Irish JM, Kotecha N and Nolan GP (2006) Mapping normal and cancer cell signalling networks: towards single-cell proteomics. *Nat Rev Cancer* 6,146–155.
- Iruela-Arispe ML (1997) Normal placentation, a tale that requires an epithelial-to-endothelial conversion. *J Clin Invest* 99,2057–2058.
- Isaka K, Usuda S, Ito H, Sagawa Y, Nakamura H, Nishi H, Suzuki Y, Li YF and Takayama M (2003) Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. *Placenta* 24,53–64.
- Itoh Y and Nagase H (1995) Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. *J Biol Chem* 270,16518–16521.
- Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K et al. (2005) Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of *Helicobacter pylori*. *Scand J Gastroenterol* 40,783–793.
- Johnson JP (1991) Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. *Cancer Metastasis Rev* 10,11–22.
- Jokhi PP, Chumbley G, King A, Gardner L and Loke YW (1993) Expression of the colony stimulating factor-1 receptor (c-fms product) by cells at the human uteroplacental interface. *Lab Invest* 68,308–320.
- Jokhi PP, King A, Jubinsky PT and Loke YW (1994) Demonstration of the low affinity alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-R alpha) on human trophoblast and uterine cells. *J Reprod Immunol* 26,147–164.
- Jones CJ, Hartmann M, Blaschitz A and Desoye G (1993) Ultrastructural localization of insulin receptors in human placenta. *Am J Reprod Immunol* 30,136–145.
- Kaiser U, Auerbach B and Oldenburg M (1996) The neural cell adhesion molecule NCAM in multiple myeloma. *Leuk Lymphoma* 20,389–395.
- Kasai K, Shik SS and Yoshida Y (1982) Production and localization of human prolactin in placenta and decidua in early and at term normal pregnancy. *Int J Biol Res Pregnancy* 3,25–29.
- Kauma S, Huff T, Krystal G, Ryan J, Takacs P and Turner T (1996) The expression of stem cell factor and its receptor, c-kit in human endometrium and placental tissues during pregnancy. *J Clin Endocrinol Metab* 81,1261–1266.

- Kauma S, Hayes N and Weatherford S (1997) The differential expression of hepatocyte growth factor and met in human placenta. *J Clin Endocrinol Metab* 82,949–954.
- Khandwala HM, McCutcheon IE, Flyvbjerg A and Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. *Endocr Rev* 21,215–244.
- Kim SJ, Shiba E, Taguchi T, Watanabe T, Tanji Y, Kimoto Y, Izukura M and Takai SI (1997) Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. *Anticancer Res* 17,1373–1378.
- Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW and Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. *JAMA* 287,1671–1679.
- Kita N, Mitsushita J, Ohira S, Takagi Y, Ashida T, Kanai M, Nikaido T and Konishi I (2003) Expression and activation of MAP kinases, ERK1/2, in the human villous trophoblasts. *Placenta* 24,164–172.
- Klein U and Von Figura K (1976) Partial purification and characterization of heparan sulfate specific endoglucuronidase. *Biochem Biophys Res Commun* 73,569–576.
- Knofler M, Sooranna SR, Daoud G, Whitley GS, Markert UR, Xia Y, Cantiello H and Hauguel-de Mouzon S (2005) Trophoblast signalling, knowns and unknowns—a workshop report. *Placenta* 26(Suppl A),S49–S51.
- Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR and Wilson JL (2005) The inflammatory cytokine tumour necrosis factor- α regulates chemokine receptor expression on ovarian cancer cells. *Cancer Res* 65,10355–10362.
- Kwon S, Kang SH, Ro J, Jeon CH, Park JW and Lee ES (2005) The melanoma antigen gene as a surveillance marker for the detection of circulating tumour cells in patients with breast carcinoma. *Cancer* 104,251–256.
- Laatikainen T, Saijonmaa O, Salminen K and Wahlstrom T (1987) Localization and concentrations of beta-endorphin and beta-lipotrophin in human placenta. *Placenta* 8,381–387.
- Laban C, Bustin SA and Jenkins PJ (2003) The GH-IGF-I axis and breast cancer. *Trends Endocrinol Metab* 14,28–34.
- Lacroix MC, Guibourdenche J, Fournier T, Laurendeau I, Igout A, Goffin V, Pantel J, Tsatsaris V and Evain-Brion D (2005) Stimulation of human trophoblast invasion by placental growth hormone. *Endocrinology* 146,2434–2444.
- Ladines-Llave CA, Maruo T, Manalo AS and Mochizuki M (1991) Cytologic localization of epidermal growth factor and its receptor in developing human placenta varies over the course of pregnancy. *Am J Obstet Gynecol* 165,1377–1382.
- Larue L and Bellacosa A (2005) Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. *Oncogene* 24,7443–7454.
- Lei KJ, Sartwell AD, Pan CJ and Chou JY (1992) Cloning and expression of genes encoding human pregnancy-specific glycoproteins. *J Biol Chem* 267,16371–16378.
- Leone A, Flatow U, King CR, Sandeen MA, Margulies IM, Liotta LA and Steeg PS (1991) Reduced tumour incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. *Cell* 65,25–35.
- Leslie KK, Watanabe S, Lei KJ, Chou DY, Plouzek CA, Deng HC, Torres J and Chou JY (1990) Linkage of two human pregnancy-specific beta 1-glycoprotein genes, one is associated with hydatidiform mole. *Proc Natl Acad Sci USA* 87,5822–5826.
- Lewis TS, Shapiro PS and Ahn NG (1998) Signal transduction through MAP kinase cascades. *Adv Cancer Res* 74,49–139.
- Librach CL, Werb Z, Fitzgerald ML, Chiu K, Corwin NM, Esteves RA, Grobely D, Galardy R, Damsky CH and Fisher SJ (1991) 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. *J Cell Biol* 113,437–449.
- Liotta LA (1984) Tumour invasion and metastases, role of the basement membrane. Warner-Lambert Parke-Davis Award lecture. *Am J Pathol* 117,339–348.
- Liu J, Chakraborty C, Graham CH, Barbin YP, Dixon SJ and Lala PK (2003) Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. *Exp Cell Res* 286,138–151.
- Loke YW and King A (1995) *Human Implantation*. Cambridge University Press, Cambridge.
- Lotem J and Sachs L (1996) Control of apoptosis in hematopoiesis and leukemia by cytokines, tumour suppressor and oncogenes. *Leukemia* 10,925–931.
- Lotem J, Netanel D, Domany E and Sachs L (2005) Human cancers overexpress genes that are specific to a variety of normal human tissues. *Proc Natl Acad Sci USA* 102,18556–18561.
- Luo SM, Tan WM, Deng WX, Zhuang SM and Luo JW (2005) Expression of albumin, IGF-1, IGFBP-3 in tumour tissues and adjacent non-tumour tissues of hepatocellular carcinoma patients with cirrhosis. *World J Gastroenterol* 11,4272–4276.
- MacPhee DJ, Mostachfi H, Han R, Lye SJ, Post M and Caniggia I (2001) Focal adhesion kinase is a key mediator of human trophoblast development. *Lab Invest* 81,1469–1483.
- Maeno K, Masuda A, Yanagisawa K, Konishi H, Osada H, Saito T, Ueda R and Takahashi T (2006) Altered regulation of c-jun and its involvement in anchorage-independent growth of human lung cancers. *Oncogene* 25,271–277.
- Maglione D, Guerriero V, Viglietto G, Delli-Bovi P and Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. *Proc Natl Acad Sci USA* 88,9267–9271.
- Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, Del Vecchio S, Lei KJ, Chou JY and Persico MG (1993) Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14. *Oncogene* 8,925–931.
- Malatesta M, Mannello F, Luchetti F, Marcheggiani F, Condemi L, Papa S and Gazzanelli G (2000) Prostate-specific antigen synthesis and secretion by human placenta, a physiological kallikrein source during pregnancy. *J Clin Endocrinol Metab* 85,317–321.
- Malumbres M and Barbacid M (2003) RAS oncogenes, the first 30 years. *Nat Rev Cancer* 3,459–465.
- Maquoi E, Polette M, Nawrocki B, Bischof P, Noel A, Pintiaux A, Santavicca M, Schaaps JP, Pijnenborg R, Birembaut P *et al.* (1997) Expression of stromelysin-3 in the human placenta and placental bed. *Placenta* 18,277–285.
- Marcillac I, Troalen F, Bidart JM, Ghillani P, Ribrag V, Escudier B, Malassagne B, Droz JP, Lhomme C, Rougier P *et al.* (1992) Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. *Cancer Res* 52,3901–3907.
- Martin TA, Watkins G and Jiang WG (2005) KiSS-1 expression in human breast cancer. *Clin Exp Metastasis* 22,503–511.
- Maruo T and Mochizuki M (1987) Immunohistochemical localization of epidermal growth factor receptor and myc oncogene product in human placenta, implication for trophoblast proliferation and differentiation. *Am J Obstet Gynecol* 156,721–727.
- Maruo T, Matsuo H, Otani T and Mochizuki M (1995) Role of epidermal growth factor (EGF) and its receptor in the development of the human placenta. *Reprod Fertil Dev* 7,1465–1470.
- McCracken SA, Grant KE, MacKenzie IZ, Redman CW and Mardon HJ (1999) Gestational regulation of granulocyte-colony stimulating factor receptor expression in the human placenta. *Biol Reprod* 60,790–796.
- Meisser A, Chardonnens D, Campana A and Bischof P (1999) Effects of tumour necrosis factor- α , interleukin-1 α , macrophage colony stimulating factor and transforming growth factor beta on trophoblastic matrix metalloproteinases. *Mol Hum Reprod* 5,252–260.
- Meunier-Carpentier S, Dales JP, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, Lavaut MN, Allasia C and Charpin C (2005) Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. *Int J Oncol* 26,977–984.
- Mignatti P, Robbins E and Rifkin DB (1986) Tumour invasion through the human amniotic membrane, requirement for a proteinase cascade. *Cell* 47,487–498.
- Mock P, Frydman R, Bellet D, Chassin D, Bischof P, Campana A and Bidart JM (2000) Expression of pro-EPIL peptides encoded by the insulin-like 4 (INSL4) gene in chromosomally abnormal pregnancies. *J Clin Endocrinol Metab* 85,3941–3944.
- Mol JA, Henzen-Logmans SC, Hageman P, Misdorp W, Blankenstein MA and Rijnberk A (1995) Expression of the gene encoding growth hormone in the human mammary gland. *J Clin Endocrinol Metab* 80,3094–3096.
- Montell DJ (2005) Anchors away! Fos fosters anchor-cell invasion. *Cell* 121,816–817.
- Mullen CA (1998) Review, analogies between trophoblastic and malignant cells. *Am J Reprod Immunol* 39,41–49.
- Murata K, Maruo T, Matsuo H and Mochizuki M (1994) [Insulin-like growth factor-I (IGF-I) as a local regulator of proliferation and differentiation of villous trophoblasts in early pregnancy]. *Nippon Sanka Fujinka Gakkai Zasshi* 46,87–94.
- Nakai Y, Nonomura N, Oka D, Shiba M, Arai Y, Nakayama M, Inoue H, Nishimura K, Aozasa K, Mizutani Y *et al.* (2005) KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumours. *Biochem Biophys Res Commun* 337,289–296.
- Nakajima M, Irimura T and Nicolson GL (1988) Heparanases and tumour metastasis. *J Cell Biochem* 36,157–167.

- Nakano T, Oka K, Ishikawa A and Morita S (1997) Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. *Cancer* 79,513–520.
- Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S and Davaris P (2002) Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. *J Pathol* 197,307–313.
- Nawrocki B, Polette M, Marchand V, Maquoui E, Beorchia A, Tournier JM, Foidart JM and Birembaut P (1996) Membrane-type matrix metalloproteinase-1 expression at the site of human placentation. *Placenta* 17,565–572.
- Nesland JM, Holm R, Johannessen JV and Gould VE (1988) Neuroendocrine differentiation in breast lesions. *Pathol Res Pract* 183,214–221.
- Nittka S, Gunther J, Ebisch C, Erbersdobler A and Neumaier M (2004) The human tumour suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis. *Oncogene* 23,9306–9313.
- Niyazi M, Ghazizadeh M, Konishi H, Kawanami O, Sugisaki Y and Araki T (2003) Expression of p73 and c-Abl proteins in human ovarian carcinomas. *J Nippon Med Sch* 70,234–242.
- O'Brien SN, Welter BH and Price TM (1999) Presence of leptin in breast cell lines and breast tumours. *Biochem Biophys Res Commun* 259,695–698.
- O'Brien PJ, Koi H, Parry S, Brass LF, Strauss JF 3rd, Wang LP, Tomaszewski JE and Christenson LK (2003) Thrombin receptors and protease-activated receptor-2 in human placentation, receptor activation mediates extravillous trophoblast invasion in vitro. *Am J Pathol* 163,1245–1254.
- Ohlsson R, Holmgren L, Glaser A, Szpecht A and Pfeifer-Ohlsson S (1989) Insulin-like growth factor 2 and short-range stimulatory loops in control of human placental growth. *EMBO J* 8,1993–1999.
- Ohlsson R, Glaser A, Holmgren L and Franklin G (1993) The molecular biology of placental development. In Redman CWG, Sargent IL and Starkey PM (eds) *The Human Placenta*. Blackwell Scientific Publications, Oxford, pp. 33–81.
- Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y et al. (2001) Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. *Nature* 411,613–617.
- Oikawa S, Inuzuka C, Kuroki M, Matsuoka Y, Kosaki G and Nakazato H (1989) A pregnancy-specific beta 1-glycoprotein, a CEA gene family member, expressed in a human promyelocytic leukemia cell line, HL-60, structures of protein, mRNA and gene. *Biochem Biophys Res Commun* 163,1021–1031.
- Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M et al. (1993) Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. *Cancer Res* 53,1696–1701.
- Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P and Basset P (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. *Proc Natl Acad Sci USA* 92,2730–2734.
- Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L (2006) VEGF receptor signalling – in control of vascular function. *Nat Rev Mol Cell Biol* 7,359–371.
- Otani T, Minami S, Yamoto M and Umesaki N (2001) Production of activin A in hyperplasia and adenocarcinoma of the human endometrium. *Gynecol Oncol* 83,31–38.
- Otte JM, Otte C, Beckedorf S, Schmitz F, Vonderhaar BK, Folsch UR, Kloehn S, Herzig KH and Monig H (2003) Expression of functional prolactin and its receptor in human colorectal cancer. *Int J Colorectal Dis* 18,86–94.
- Oya M, Mikami S, Mizuno R, Marumo K, Mukai M and Murai M (2005) C-jun activation in acquired cystic kidney disease and renal cell carcinoma. *J Urol* 174,726.
- Ozturk M, Brown N, Milunsky A and Wands J (1988) Physiological studies of human chorionic gonadotropin and free subunits in the amniotic fluid compartment compared to those in maternal serum. *J Clin Endocrinol Metab* 67,1117–1121.
- Parish CR, Coombe DR, Jakobsen KB, Bennett FA and Underwood PA (1987) Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. *Int J Cancer* 40,511–518.
- Parish CR, Freeman C and Hulett MD (2001) Heparanase, a key enzyme involved in cell invasion. *Biochim Biophys Acta* 1471,M99–M108.
- Park JS, Namkoong SE, Lee HY, Kim SJ, Hong KJ, Kim IS, Kim KU and Shim BS (1992) Expression and amplification of cellular oncogenes in human developing placenta and neoplastic trophoblastic tissue. *Asia Oceania J Obstet Gynaecol* 18,57–64.
- Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S, Vandenbunder B and Fafeur V (2002) Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. *Oncogene* 21,2309–2319.
- Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J et al. (2005) Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. *Anticancer Res* 25,3387–3391.
- Petraglia F, Calza L, Giardino L, Sutton S, Marrama P, Rivier J, Genazzani AR and Vale W (1989) Identification of immunoreactive neuropeptide-gamma in human placenta, localization, secretion, and binding sites. *Endocrinology* 124,2016–2022.
- Petraglia F, Gallinelli A, Grande A, Florio P, Ferraris S, Genazzani AR, Ling N and DePaolo LV (1994) Local production and action of follistatin in human placenta. *J Clin Endocrinol Metab* 78,205–210.
- Petraglia F, Florio P, Nappi C and Genazzani AR (1996) Peptide signaling in human placenta and membranes, autocrine, paracrine, and endocrine mechanisms. *Endocr Rev* 17,156–186.
- Pfeifer-Ohlsson S, Goustin AS, Rydner J, Wahlstrom T, Bjersing L, Stehelin D and Ohlsson R (1984) Spatial and temporal pattern of cellular myc oncogene expression in developing human placenta, implications for embryonic cell proliferation. *Cell* 38,585–596.
- Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D and Imhof BA (1995) CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. *J Cell Biol* 130,451–460.
- Pinto-de-Sousa J, David L, Almeida R, Leitao D, Preto JR, Seixas M and Pimenta A (2002) c-erb B-2 expression is associated with tumour location and venous invasion and influences survival of patients with gastric carcinoma. *Int J Surg Pathol* 10,247–256.
- Plantefaber LC and Hynes RO (1989) Changes in integrin receptors on oncogenically transformed cells. *Cell* 56,281–290.
- Pollak MN, Schernhammer ES and Hankinson SE (2004) Insulin-like growth factors and neoplasia. *Nat Rev Cancer* 4,505–518.
- Pollheimer J and Knofler M (2005) Signalling pathways regulating the invasive differentiation of human trophoblasts, a review. *Placenta* 26(Suppl A),S21–S30.
- Poste G and Fidler IJ (1980) The pathogenesis of cancer metastasis. *Nature* 283,139–146.
- Pugh CW and Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia, role of the HIF system. *Nat Med* 9,677–684.
- Qiu Q, Yang M, Tsang BK and Gruslin A (2004a) Both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signalling are required in epidermal growth factor-induced human trophoblast migration. *Mol Hum Reprod* 10,677–684.
- Qiu Q, Yang M, Tsang BK and Gruslin A (2004b) EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. *Reproduction* 128,355–363.
- Quenby S, Brazeau C, Drakeley A, Lewis-Jones DI and Vince G (1998) Oncogene and tumour suppressor gene products during trophoblast differentiation in the first trimester. *Mol Hum Reprod* 4,477–481.
- Redman CW (1997) Cytotrophoblasts, masters of disguise. *Nat Med* 3,610–611.
- Redman CW, Sargent IL and Starkey PM (1993) *The Human Placenta*. Blackwell Scientific Publications, Oxford.
- Resnick MB, Routhier J, Konkin T, Sabo E and Pricolo VE (2004) Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer, a tissue microarray study. *Clin Cancer Res* 10,3069–3075.
- Reubi JC, Waser B, Vale W and Rivier J (2003) Expression of CRF1 and CRF2 receptors in human cancers. *J Clin Endocrinol Metab* 88,3312–3320.
- Rivas CI, Vera JC, Delgado-Lopez F, Heaney ML, Guaiquil VH, Zhang RH, Scher HI, Concha II, Nualart F, Cordon-Cardo C et al. (1998) Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. *Blood* 91,1037–1043.
- Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E and Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. *EMBO J* 9,467–474.
- Romero P, Blick M, Talpaz M, Murphy E, Hester J and Gutterman J (1986) C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies. *Blood* 67,839–841.
- Roncagli M, Bullfamante G, Viale G, Springall DR, Alfano R, Comi A, Maggioni M, Polak JM and Coggi G (1994) C-myc and tumour suppressor gene product expression in developing and term human trophoblast. *Placenta* 15,399–409.
- Roy-Choudhury S, Sen-Majumdar A, Murthy U, Mishra VS, Kliman HJ, Nestler JE, Strauss JF 3rd and Das M (1988) Biosynthesis and turnover of

- a 34-kDa protein growth factor in human cytotrophoblasts. *Eur J Biochem* 172,777–783.
- Ruddon RW (1995) *Cancer Biology*. Oxford University Press, New York, Oxford.
- Sajjonmaa O, Laatikainen T and Wahlstrom T (1988) Corticotrophin-releasing factor in human placenta, localization, concentration and release in vitro. *Placenta* 9,373–385.
- Saito S, Sakakura S, Enomoto M, Ichijo M, Matsumoto K and Nakamura T (1995) Hepatocyte growth factor promotes the growth of cytotrophoblasts by the paracrine mechanism. *J Biochem (Tokyo)* 117,671–676.
- Saji H, Nakamura H, Awut I, Kawasaki N, Hagiwara M, Ogata A, Hosaka M, Saijo T, Kato Y and Kato H (2003) Significance of expression of TGF- β in pulmonary metastasis in non-small cell lung cancer tissues. *Ann Thorac Cardiovasc Surg* 9,295–300.
- Sakakibara T, Hibi K, Koike M, Fujiwara M, Koderia Y, Ito K and Nakao A (2005) Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. *Br J Cancer* 93,799–803.
- Sapi E (2004) The role of CSF-1 in normal physiology of mammary gland and breast cancer, an update. *Exp Biol Med (Maywood)* 229,1–11.
- Sarkar S, Kacinski BM, Kohorn EI, Merino MJ, Carter D and Blakemore KJ (1986) Demonstration of myc and ras oncogene expression by hybridization in situ in hydatidiform mole and in the BeWo choriocarcinoma cell line. *Am J Obstet Gynecol* 154,390–393.
- Sasagawa M, Yamazaki T, Sudo Y, Kanazawa K and Takeuchi S (1987) [Immunohistochemical localization of hCG alpha, hCG beta CTP, hPL and SP1 on villous and extravillous trophoblasts in normal human pregnancy]. *Nippon Sanka Fujinka Gakkai Zasshi* 39,1073–1079.
- Sastry BV, Barnwell SL, Tayeb OS, Janson VE and Owens LK (1980) Occurrence of methionine enkephalin in human placental villus. *Biochem Pharmacol* 29,475–478.
- Savarese TM, Campbell CL, McQuain C, Mitchell K, Guardiani R, Quesenberry PJ and Nelson BE (2002) Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. *Cytokine* 17,324–334.
- Schatz F, Krikun G, Runic R, Wang EY, Hausknecht V and Lockwood CJ (1999) Implications of decidualization-associated protease expression in implantation and menstruation. *Semin Reprod Endocrinol* 17,3–12.
- Schoppmeyer K, Kronberg J, Tannapfel A, Mossner J, Wittekind C and Caca K (2005) Predictive value of heparanase expression in the palliative therapy of pancreatic cancer. *Pancreatol* 5,570–575.
- Scippo ML, Francken F, Hooghe-Peters EL, Igout A, Velkeniers B and Hennen G (1993) Syncytiotrophoblastic localization of the human growth hormone variant mRNA in the placenta. *Mol Cell Endocrinol* 92,R7–R13.
- Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S and Shibuya M (1995) A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. *Oncogene* 10,135–147.
- Sen-Majumdar A, Murthy U, Chianese D and Das M (1986a) A specific antibody to a new peptide growth factor from human placenta, immunocytochemical studies on its location and biosynthesis. *Biochemistry* 25,634–640.
- Sen-Majumdar A, Murthy U and Das M (1986b) A new trophoblast-derived growth factor from human placenta, purification and receptor identification. *Biochemistry* 25,627–634.
- Sharkey AM, King A, Clark DE, Burrows TD, Jokhi PP, Charnock-Jones DS, Loke YW and Smith SK (1999) Localization of leukemia inhibitory factor and its receptor in human placenta throughout pregnancy. *Biol Reprod* 60,355–364.
- Sherwood DR, Butler JA, Kramer JM and Sternberg PW (2005) FOS-1 promotes basement-membrane removal during anchor-cell invasion in *C. elegans*. *Cell* 121,951–962.
- Shih IM and Kurman RJ (1999) Immunohistochemical localization of inhibin-alpha in the placenta and gestational trophoblastic lesions. *Int J Gynecol Pathol* 18,144–150.
- Shih Ie M, Hsu MY, Oldt RJ 3rd, Herlyn M, Gearhart JD and Kurman RJ (2002) The role of E-cadherin in the motility and invasion of implantation site intermediate trophoblast. *Placenta* 23,706–715.
- Shimonovitz S, Hurwitz A, Dushnik M, Anteby E, Geva-Eldar T and Yagel S (1994) Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts, a possible mechanism for control of trophoblast invasion. *Am J Obstet Gynecol* 171,832–838.
- Shiokawa S, Iwashita M, Akimoto Y, Nagamatsu S, Sakai K, Hanashi H, Kabir-Salmani M, Nakamura Y, Uehata M and Yoshimura Y (2002) Small guanosine triphosphatase RhoA and Rho-associated kinase as regulators of trophoblast migration. *J Clin Endocrinol Metab* 87,5808–5816.
- Shiraishi S, Nakagawa K, Kinukawa N, Nakano H and Sueishi K (1996) Immunohistochemical localization of vascular endothelial growth factor in the human placenta. *Placenta* 17,111–121.
- Sinkovics JG and Horvath JC (2005) Human natural killer cells, a comprehensive review. *Int J Oncol* 27,5–47.
- Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, Husnjak K, Unusic J and Pavelic K (2005) Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions, coexpression and correlation with clinicopathologic parameters. *Exp Mol Pathol* 79,42–50.
- Smith HO, Anderson PS, Kuo DY, Goldberg GL, DeVictoria CL, Boocock CA, Jones JG, Runowicz CD, Stanley ER and Pollard JW (1995) The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. *Clin Cancer Res* 1,313–325.
- Somasundar P, McFadden DW, Hileman SM and Vona-Davis L (2004) Leptin is a growth factor in cancer. *J Surg Res* 116,337–349.
- Staff AC (2001) An introduction to cell migration and invasion. *Scand J Clin Lab Invest* 61,257–268.
- Stetler-Stevenson WG, Aznavoorian S and Liotta LA (1993) Tumour cell interactions with the extracellular matrix during invasion and metastasis. *Annu Rev Cell Biol* 9,541–573.
- Strickland S and Richards WG (1992) Invasion of the trophoblasts. *Cell* 71,355–357.
- Suda T (1994) [Synthesis and release of CRF and ACTH in ectopic CRF/ACTH-producing tumours]. *Nippon Naibunpi Gakkai Zasshi* 70,17–24.
- Sugawara T, Maruo T, Otani T and Mochizuki M (1994) Increase in the expression of c-erbA and c-erbB mRNAs in the human placenta in early gestation. Their roles in trophoblast proliferation and differentiation. *Endocr J* 41,S127–S133.
- Takai N, Ueda T, Narahara H and Miyakawa I (2005) Expression of c-Ets1 protein in normal human placenta. *Gynecol Obstet Invest* 61,15–20.
- Tamiolakis D, Simopoulos C, Venizelos J, Lambropoulou M, Nikolaidou S, Tsikouras P, Koutsougeras G, Alexiadis G, Menegaki M and Papadopoulos N (2005) Distribution of somatostatin in pancreatic ductal adenocarcinoma remodels the normal pattern of the protein during foetal pancreatic development, an immunohistochemical analysis. *Clin Exp Med* 5,106–111.
- Tashima LS, Mazoujian G and Bryant-Greenwood GD (1994) Human relaxin in normal, benign and neoplastic breast tissue. *J Mol Endocrinol* 12,351–364.
- Testa JE and Quigley JP (1990) The role of urokinase-type plasminogen activator in aggressive tumour cell behavior. *Cancer Metastasis Rev* 9,353–367.
- Toker A and Yoeli-Lerner M (2006) Akt signaling and cancer: surviving but not moving on. *Cancer Res* 66,3963–3966.
- Tomita T, Poisner A and Inagami T (1987) Immunohistochemical localization of renin in renal tumours. *Am J Pathol* 126,73–80.
- Torry DS, Ahn H, Barnes EL and Torry RJ (1999) Placenta growth factor, potential role in pregnancy. *Am J Reprod Immunol* 41,79–85.
- Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES and Hsu SL (2006) Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placenta from pregnancies complicated by placenta accreta. *Placenta* 27,70–78.
- Tyrey L (1982) Human chorionic gonadotropin, structural, biologic, and immunologic aspects. *Semin Oncol* 9,163–173.
- Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J et al. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* 309,418–425.
- van Riggelen J, Buchwalter G, Soto U, De-Castro Arce J, Hausen HZ, Wasylk B and Rosl F (2005) Loss of net as repressor leads to constitutive increased c-fos transcription in cervical cancer cells. *J Biol Chem* 280,3286–3294.
- Vettriano IM, Roby J, Tolley T and Parks WC (1996) Collagenase-I, stromelysin-I, and matrilysin are expressed within the placenta during multiple stages of human pregnancy. *Placenta* 17,557–563.
- Vieira JM, Santos SC, Espadilha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S and Leite V (2005) Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin, a potential autocrine loop. *Eur J Endocrinol* 153,701–709.
- Vivanco I and Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. *Nat Rev Cancer* 2,489–501.
- Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I et al. (1999) Mammalian heparanase, gene cloning, expression and function in tumour progression and metastasis. *Nat Med* 5,793–802.
- Volm M, Drings P and Wodrich W (1993) Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. *J Cancer Res Clin Oncol* 119,507–510.

- Wada K, Sakamoto C, Matsuda K, Uchida T, Noguchi H, Mizuno H, Akamatsu T and Kasuga M (1998) Gastric epithelial cells secrete a PDGF-like peptide, a potent mitogen for human gastric fibroblasts. *Proc Soc Exp Biol Med* 217,109–115.
- Waeber G, Hurlimann J, Nicod P and Grouzmann E (1995) Immunolocalization of neuropeptide Y in human pancreatic endocrine tumours. *Peptides* 16,921–926.
- Wagner K, Peters M, Scholz A, Benckert C, Ruderisch HS, Wiedenmann B and Rosewicz S (2004) Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. *Gastroenterology* 126,1828–1843.
- Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M and Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. *J Biol Chem* 269,26988–26995.
- Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, Seiki M, Ishii S and Fujinaga K (1998) The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. *Int J Cancer* 77,128–137.
- Watkins WB and Yen SS (1980) Somatostatin in cytotrophoblast of the immature human placenta, localization by immunoperoxidase cytochemistry. *J Clin Endocrinol Metab* 50,969–971.
- Weetman AP (1999) The immunology of pregnancy. *Thyroid* 9,643–646.
- Yamashita K, Yamoto M, Shikone T, Minami S, Imai M, Nishimori K and Nakano R (1997) Production of inhibin A and inhibin B in human ovarian sex cord stromal tumours. *Am J Obstet Gynecol* 177,1450–1457.
- Yang DH, Huang W, Cui J, Shu JC, Tang SH, Zhang WJ and Liang JH (2004) The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* 3,86–89.
- Yang X, Liu F, Xu Z, Chen C, Wu X, Li G and Li J (2005) Expression of granulocyte colony stimulating factor receptor in human colorectal cancer. *Postgrad Med J* 81,333–337.
- Yoshida Y (2005) Secretion of human chorionic gonadotropin in early pregnancy. *Med Mol Morph* 38,104–111.
- Zhang X, Shu MA, Harvey MB and Schultz GA (1996) Regulation of urokinase plasminogen activator production in implanting mouse embryo, effect of embryo interaction with extracellular matrix. *Biol Reprod* 54,1052–1058.
- Zhao MD, Hu XM, Sun DJ, Zhang Q, Zhang YH and Meng W (2005) Expression of some tumour associated factors in human carcinogenesis and development of gastric carcinoma. *World J Gastroenterol* 11,3217–3221.
- Zhou Y, Damsky CH and Fisher SJ (1997a) Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? *J Clin Invest* 99,2152–2164.
- Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M and Damsky CH (1997b) Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? *J Clin Invest* 99,2139–2151.
- Zini JM, Murray SC, Graham CH, Lala PK, Kariko K, Barnathan ES, Mazar A, Henkin J, Cines DB and McCrae KR (1992) Characterization of urokinase receptor expression by human placental trophoblasts. *Blood* 79,2917–2929.

Submitted on January 16, 2006; resubmitted on August 11, 2006; accepted on September 7, 2006